Laboratory management, accreditation, quality assurance M294 International external quality evaluation on new sweat test analyzer: ISEsweat II R. Camero Tecnicas Cientificas Para Laboratorio, Spain Background-aim Introduction. The concentration of chloride in sweat remains the gold standard for confirming the diagnosis of Cystic Fibrosis. The sweat test is a tedious laboratory test that traditionally requires 3 correlative steps: stimulation, collection and analysis. A new sweat chloride analyzer that allows the direct determination of chloride in sweat using disposable cards could reduce the handling of samples and facilitate the sweat test.
The term six sigma means 99.9997% accuracy or 3.4 defect rates per million transactions. In laboratory studies, sometimes false negative, false positive or outlier values can be seen as a result of our errors. Six sigma is a method used to identify and then minimize these errors.
Six-sigma metrics has been successfully performed in clinical laboratories for nearly 20 years. In our study, we evaluated the analytical performances of fifteen tests performed in our laboratory with six sigma metrics and aimed to achieve high quality targets.
Methods
This study was conducted in Haydarpaşa Numune Education and Research Hospital Emergency Biochemistry Laboratory. Coefficient and variation (CV %) and bias % were calculated using the internal and external quality control data from January 2016 to December 2016 (12 months). The Sigma metric was estimated for 15 clinical chemistry tests [albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, direct bilirubin, urea nitrojen, creatinine, calcium, creatine kinase (CK), sodium, potassium, chlorine, glucose, lactate dehydrogenase (LDH), Magnesium ] on Abbott ARCHITECT ci8200 autoanalyzer. Sigma metrics were calculated using bias %, CV % and total allowable error (TEa) ratios of CLIA'88 and Ricos. Sigma metric equation is given below:
Sigma Metric ¼ TEa%−Bias% ð Þ =CV% Two Sigma metrics were calculated for each parameter using 2 different levels of controls (Low and high, normal and high QC etc.) close to clinical decision threshold.
Results
Sigma values were variable based on the CLIA and Ricos TEa targets. Magnessium had world performance with CLIA TEa limits, but it could not showed acceptable performans in Ricos TEa limits. On the other hand, according to both CLIA and Ricos targets, CK had the highest sigma values at both control levels (⌠1 CLIA: 14.9, ⌠ 2 CLIA: 9.3); (⌠1Ricos: 15.1, ⌠2Ricos: 9.4) and sodium had the lowest sigma values (⌠1 CLIA: 1.93, ⌠ 2 CLIA: 1.54); (⌠1Ricos: −0.07, ⌠2Ricos: −0.06). For direct bilirubin there was no specification from CLIA so we calculated sigma value of direct bilirubin from Ricos data and it had world-class performance. The other tests had sigma performance ranged between 2 and 6.
M300
The increasing quality of the services provided by Romanian medical laboratories demonstrated by the participation in external quality control C. Popa, G. Sorescu, C.G. Dinulescu CALILAB, Romania
Background-aim
Introduction. External quality control is for medical laboratories that use it as an important tool in improving processes by providing them with opportunities for improvement (OFIs), according to the World Health Organization.
The aim of this paper is to show the increase in quality of the services provided by medical laboratories in Romania by objectively analyzing the coefficients of variation of the results provided by the participants to the external quality control organized by a national provided (CALILAB).
Methods
The coefficient of variation used to assess the performance of medical laboratories has been calculated and analyzed for a variable number of 340 laboratories according to the external quality control schemes taken in the study: Serum Biochemistry and Hematology.
The value of the variation coefficients of the results reported by the medical laboratories participating in the external quality control organized by CALILAB in Romania for the analyzes / parameters of the studied schemes was compared with the value of the coefficients of variation presented in the literature by other international providers of external quality control.
Results
The comparison results highlighted: -^the increasing in quality of the services provided by medical laboratories in Romania by the decrease the values of the coefficients of variation for the parameters analyzed in the external quality control organized by CALILAB in the period 2008-2018; -^the values of the coefficients of variance for the parameters analyzed in the external quality control organized by CALILAB in 2018 are lower than the values of the coefficients of variation of the same parameters established by the consensus of the providers of external quality control at international level.
Conclusions
The quality of the services provided by medical laboratories in Romania has been highlighted by the decrease of values of the coefficients of variation of the results by the laboratories participating in the external quality control organized by CALILAB, coefficients of variation lower than the values of the established by the consensus of the providers of external quality control at international level. 
Background-aim
According to ISO 15189:2012, clinical laboratories need to compare procedures, analyzers and methods and assess the interchangeability and equivalence of test results from identic procedures or analyzers. This verification process makes it possible to establish preventive corrective actions towards an improvement in patient safety.
Our objective was to apply the verification protocol for test result interchangeability of the accredited biochemical tests in our laboratory, in accordance with document EP-31-A-IR (CLSI). The second aim of this project was to compare the results of this interchangeability verification process with the previous one, carried out 3 years ago using the same technology.
Methods
Serum, urine, K3EDTA-whole blood and lithium heparin-whole blood patient samples and certificated control materials were used for the study of 52 accredited biochemistry tests in our laboratory.
Approximate analyte concentration was estimated on the basis of clinical decision levels and known imprecision; the latter obtained from the intraserial standard deviation (RS, n = 20) and the total standard deviation (TS, n = number of controls assayed in a ε6month period).
Magnitudes were defined as interchangeable when the difference between the average results of each autoanalyzer (DbM)bLimit of acceptability (LoA), which was calculated by following the document EP-31-A-IR (CLSI).
Results
Interchangeability of all analyzers was verified, except for TSH and GGT. As a corrective action, were removed the conflictive tests from the uninterchangeable autoanalyzers, although in response to their demand and loading by equipment, TSH was implanted in a newly acquired autoanalyzer.
The results highlight the importance of this kind of studies, given that in the previous one, these tests were interchangeable. This shows the variability over time of the results, as a consequence of equipment wear, changes in the reference material, new laboratory staff…
Conclusions
Clinical laboratories must periodically verify the interchangeability of the test results and establish the pertinent corrective actions, as well as to evaluate the effectiveness of the adopted measures, in order to improve result quality and to ensure patient safety. Background-aim Introduction. The overall health impact of Influenza varies widely from season to season, it has an effect on the Emergency Laboratory workload.
Aim. The aim is to test diagnosis of influenza impact on Emergency Laboratory workload, trough the last two influenza seasons.
Methods. It is an observational retrospective study. An estimation of diagnosis of Influenza workload for the Emergency Laboratory was done for the 2016-2017 ( November2016-April 2017) and for the 2017-2018 (November 2017-April 2018) influenza seasons. There was obtained the number of tests for detection of Influenza virus performed , from Laboratory Information System (Omega-Roche Diagnostics) and also was used the Catálogo de Pruebas de BioquímicaClínica y Biología Molecular. Consellería de Sanitat. Generalitat Valenciana to calculate the relative unit cost (CRU) produced each period.
Results. The resultant Emergency Laboratory workload due to diagnosis of Influenza was 17741 CRU, in the first season 2016-2017, and 27866 CRU, in the season 2017-2018 (+57 % higher)
Influenza diagnosis implies a considerable workload for the Emergency Laboratory.
The workload has varied widely trough the two seasons. Compared with the previous season, 2017-2018 Influenza season, one of the most severe in this century, has supposed a serious increase in the Emergency Laboratory workload.
The Catálogo de Pruebas de BioquímicaClínica y Biología Molecular. Consellería de Sanitat. Generalitat Valenciana, agreed by professionals, enables workload evolution study. 
Background-aim
So far, the IVD applications like TBNK / CD34 are provided by Flow Cytometry (FCM) manufactures. Then, they also provide the Quality Control (QC) material and the software functions for QC management and Report. However, almost FCM laboratories (Labs) do the test based on the Laboratory Developed Test (LDT), and also do the QC based on the Standard Operation Procedure (SOP) that is managed by each FCM Lab. The conventional FCM software doesn't have the QC management function for LDT, so original QC chart is created and the QC results are managed in the each Labs. It is complicated for the FCM testing workflow. Therefore we developed the "Panel Setup/QC" function, it includes the management and the report function of QC for LDT, and decrease complicated steps and improve the FCM testing Workflow.
Methods

1.
Adjust the Gain/Photomultiplier voltage to the optimized value for analysis by using the QC material based on SOP in Lab. 2. Create the compensation table. 3 . Save the measurement conditions as the panel information. 4 . Create the QC file for LDT and set the baseline and the upper/lower limits for each channel. 5. Measure the QC material in daily. 6. Report the QC chart.
Results
About QC, Adjustment of Gain/PMTV and Compensation, Running sample, we evaluated the difference in the case of between the manual operations and using the "Panel Setup/QC" function. The usage materials that we assume the TBNK 6 color of LDT panel are followings.
-Sample: CD Chex (Streck) -reagents: Kombitest 6 color cocktail (Exbio) -Beads for compensation: CompTrol beads with CD8 antibody with the different flurochromes
The results are followings.
I. The steps for FCM testing Workflow are decreased in 56.5% by using the "Panel Setup/QC" function.
(there are 23 steps for the manual operations, but only 10 steps by using it.)
Conclusions
We can realize the followings for LDT by developing the "Panel Setup/QC" function. 
Background-aim
Considering that on average 70% of clinical laboratory errors occur in the pre-analitycal phase of total testing process, the aim of this study is to analyze the specific quality indicators-QIs and to identify the relevants ones to inhance patient safety by continous improvement of our clinical laboratory activity.
Methods
Prospective study, carried out for 18 months in a clinical laboratory for in-patients, by analyzing collected data on e-requests and types of biological samples received for clinical chemistry and hematology compartments. The calculated values obtained for the 12 selected Qis were expressed as %, defects per million -DPM and on six sigma scale.
Results
During the follow-up time we had received 29454 request forms and 36746 biological samples from the clinical departments of the stationary. The data analysis of selected Qis values showed the highest % rate for the number of inpatients requests with erroneous data entry(test name)-Pre InpMT and the number of misidentified requests-PreMisR(0.89 and 0.94%),respectively the lower one for the unidentified sample-PreUnIns (0.065%).The 3.9 Sigma score value associated to the the critical errors corresponding to the Pre InpMT and to PreMisR showed an immediate need to training for all authorized staff as mandatory corrective action in the prepreanalytical phase.We have notice a good acceptability -4.4 sigma value-for the hemolysed primary samples evaluated by visual inspection. Reporting errors Sigma score 4.4 associated to the biological samples for hematology compartment was over the Sigma value 4.2 obtained for the clinical biochemistry specimens. Our lab proved a good performance showed by a Sigma score between 4.1 to 4.4 for 8 monitored Qis, but the accuracy improvement of entering data process in e-request form it' s a must.
Conclusions
Study results were used as entry data for management analysis to ensure risk mitigation especially in the extraanalytical phase by improving communication and training of medical staff in order to increase lab performance 
Background-aim
Pre analytical variables account for 45-60% of the total errors in a clinical laboratory. They are encountered principally in the following areas: improper test request, misidentification of the patient, labeling errors, sample collected in unsuitable vacutainer/additive, inadequate volume, compromised sample integrity and delayed/ improper transport. A risk assessment analysis of the pre-analytical phase was performed in the Clinical Laboratory of a six-fifty bedded tertiary care hospital in India. Aims of the study included improvement of in-time sampling, reduction in sample rejection and increased patient satisfaction.
Methods
FMEA (Failure Mode effect Analysis) was used as a tool for Risk Assessment of pre-analytical processes. The probable areas of risk in the pre analytical phase were first identified and a RPI (Risk Priority Index= Severity × Detectability × Probability) was assigned to each source of error. In areas where the RPI was above 50 (out of a total of 125), appropriate actions were proposed to reduce the estimated risk. The effectiveness of the actions taken shall be reviewed every six months.
Results
More than 90% of the samples requiring re-dos were from the inpatients department. The primary causes of rejection included clotted and haemolysed samples, quantity not sufficient, wrong sample, wrong container and doubtful integrity of samples. They were attributed to incorrect sample collection practices (wrong container, wrong barcode), incorrect phlebotomy practices for serum samples (collection with needle and syringe, opening the cap of the vacutainer, pushing the piston of the syringe, inadequate filling resulting in altered plasma-anticoagulant ratio). This reflects inadequate training of the nursing personnel involved in sample collection in the IPD.
Conclusions
Extensive training sessions on "Best Practices in Phlebotomy" were organized for nursing staff every month. This was to ensure training of all new staff and re-training of the existing personnel. In addition, regular trainings were also imparted on appropriate sample collection practices. 
Background-aim
Meir Medical Center clinical laboratories catalog contains over 450 tests, in a wide range of fields. However, there are tests that require a dedicated instrument, a special method of performance or performed only at national centers. For this purpose, we have established a process of tests delivery for outsourcing. The process involves several factors within the hospital and outside it, including hospital departments, lab reception office, transportation unit and the laboratories operating at the outsourcing sites. Accordingly, to ensure its success, process control is required to provide efficient and continuous service. Our aim was to developed a process map in order to locate control points and to establish a tight control on the whole process.
Methods
Several stages were defined, including communication improvements with all outsourcing labs, a wide electronic lab catalog updating and full documentation of all incoming outsourcing lab result reports. We also preformed a trial period to test improvements feasibility.
Results
As of June 2016, the control has entered into a defined monthly framework. The monthly control data for all 2017 was summarized and analyzed. In terms of overall output, a 7% increase in number of samples sent for outsourcing compared to 2016, 2509 samples in 2017 versus 2341 samples in 2016. In measuring the control process performance, 99.1% results were obtained in 2017, 2435 results out of 2456 of samples shipped for outsourcing. This is in comparison to 42% at the beginning of process map designing. In addition, by these controlled processes we performed a full measurement of samples turnaround time, from sampling transport date until the result received from all outsourcing sites.
Conclusions
The outsourcing process is a central part of the laboratory services for the medical staff, by enables comprehensive laboratory service and continuity of patient's treatment. Results shows we have succeeded by tight control process to significantly improve the tractability of outsources lab results. In this way we have effectively expanded the control limits of our clinical laboratory division, which strives to continuously service improvements. doi:10.1016/j.cca.2019.03.1059
M307
Survey on stat tests in Catalonia clinical laboratories
A. Arbiol-Roca, D. Dot-Bach Laboratori Clínic Territorial Metropolitana Sud, L'Hospitalet de Llobregat, Barcelona, Spain
Background-aim
In order to know the state of the art and new trends on Stat Tests, the Catalan Association of Clinical Laboratory Sciences (ACCLC) did a survey on the vast majority of Clinical Laboratories in Catalonia.
Methods
During 2017, the ACCLC distributed an online survey to 69 hospital laboratories. A web-survey with 12 point questionnaire was sent to investigate: laboratory model, degree of computerisation, human resources, quality control, validation of results and critical results, among others. The collected information was analyzed.
Results
Survey participation was (41/69) 59%. There were 8 tertiary hospitals (19.5%) (ε400 patients/day) and 21 secondary hospitals (51.2%) (ε170 patients/day). There were 28 teaching hospitals (68.3%) and 26 hospitals with Intensive Unit Care (63.4%). The 53.7% were public hospitals. The 68.3% of stat laboratories, biochemistry and haematology were integrated and microbiology separated. The 60.9% of stat laboratories were integrated in part with laboratory core. Requests were done electronically by 75.6%. The majority of laboratories (48.8%) had been 100-300 request/day with 1000-3000 tests/day. The 46.3% of laboratories were using International and conventional units in clinical reports. All laboratories participated in internal and external quality assessment programs. The vast majority of laboratories reported critical results (97.6%). These values are established by consensus with clinicians (59%). Still telephone was the main communication system (69%). Clinicians or nurse were the responsible for receiving the critical value notification (80%). The majority of laboratories validation was by laboratory medical specialist and laboratory technician (31.7%) or only by technician (24.4%). With regard to human resources, the vast majority of stat laboratories have been one medical specialist (biochemistry or analysis) (75%) and in some laboratories also there were a microbiology or haematology specialist. In 75.6% there were a specialist on call 24 hours/day by physically present or telephonically. Laboratory staff was consisted by technicians (100%) and nurses (29.3%).
Conclusions
This survey was helpful in order to know the state of the art in stat tests laboratories in Catalonia. doi:10.1016/j.cca.2019.03.1060
M308
Sigma metrics for assessing the analytical quality of the new multi-test VITROS® XT chemistry products slides 1 
Background-Aim
The new VITROS® XT Chemistry Products Slides (UREA-CREA, ALTV-AST*, TRIG-CHOL*, ALB-TP*, GLU-Ca*, and TBIL-ALKP*) have been developed with dual test capability for use on the VITROS XT 7600 Integrated System. The analytical performance of these new XT assays has been evaluated for analytic quality using the sigma metrics methodology.
Methods
For precision determinations, the total within-lab precision was calculated with quality control and patient sample using two replicates per day, twice per day over 20 days (total n = 80) following CLSI EP5 guidelines. For bias determinations, two different methods were used. For the first method over one hundred patient samples spanning the measuring range were analyzed in singleton on a XT 7600 System against a reference method. The data was analyzed following CLSI EP9 guidelines using a Passing-Bablok regression, and the percent bias was calculated from the regression line. The second method used the College of American Pathologists (CAP) 2018 Chemistry survey fluids to calculate the percent bias. Two different allowable total error (TE a ) values (Ricos and CLIA) were used to calculate the sigma metrics using the coefficient of variation (CV) and bias as determined above: sigma metrics = (TE a − %Bias)/CV.
Results
Using the regression equation from the patient samples to determine Six Sigma quality, six of the XT assays (UREA, TRIG*, GLU*, TBIL*, ALTV* and AST*) had greater than six sigma performance versus the Ricos TE a . Another three XT assays (CREA, CHOL* and ALKP*) had greater than five sigma performance. The remaining three XT assays (Ca*, ALB* and TP*) had less than three sigma performance due to the very small Ricos TE a (2.55%, 4.07%, and 3.63% respectively). When evaluating the assay quality versus the CLIA TE a requirement, all assays except ALB* had greater than six sigma performance and ALB* had greater than five sigma performance. The results were substantially equivalent when the sigma metric were determined using the CAP survey fluids for the bias estimate instead of the regression equation.
Conclusions
The data presented here demonstrate that the new XT Micro-Slides on the XT Systems show excellent analytical performance for precision and accuracy when judged using the Sigma Metrics methodology against the CLIA TE a requirement. 
Background-aim
The aim was to evaluate the evolution of preanalytical quality indicators (QI) during 2014-2017 in order to evaluate quality specifications (QS) previously established by the clinical laboratories of Catalonian Health Institute (Spain) consensus after ten years of experience.
Methods
Yearly average was recorded for each IQ and laboratory, and the average of the yearly interlaboratory median was calculated to assess intergroup evolution.
For samples, IQ formulas were modified, and the activity of the most requested test in each type of specimen was chosen as denominator: creatinine, complete blood cell, prothrombin time or diuresis for serum, EDTA, plasma-citrate-coagulation (Plasma-CC), and 24h urine sample, respectively. For serum and first morning urine sample, IQs were calculated respect to the total number of requests to evaluate its evolution respect to the previous QS. Hemolyzed serum sample QI was calculated differently with the use of automated hemolysis index detection in all laboratories.
Results
QS for total errors in requests, requests with data missing and total errors in samples improved (0.96% vs 1.3%), (0.82% vs 1.31%) and (3% vs 5%), respectively. QS for total errors in serum with respect to the total requests worsened (0.6% vs δ0.50%). QS for total errors in first morning urine improved (1.22% vs. 1.25%). Incorrect patient data also improved (0.03%-0.01%), but could not reach desirable 0% QS as sentinel QI.
New QS for total errors in different types of samples based on the activity were: Serum (1.16%), EDTA (0.67%), Plasma-CC (2.29%) and 24h urine (8.81%), respectively.
Hemolyzed serum QI for primary care (2.07%-1.01%) and hospitals (3.91%-1.71%) centers improved in the last year but the QS has not yet been established due to the variability between laboratories.
Conclusions
The results of the QI will be used as new QS. Organizational changes such as the fusion of hospital and primary laboratories may have an impact on the results of the QI (increase in the number of samples, changes in the sample containers, analyzers, etc.). A more reliable denominator in different types of samples avoid that QI of less frequent samples can be underestimated. The monitoring of QI allows take actions to avoid occurrence of errors in order to increase patient safety. 
Methods
The critical values are analyzed retrospectively in a period of five months.
Results
We obtained a total of 467 critical values, from which a percentage of 44% were notified (No. 207). The rest of them weren't notified because they had similar previous values. Regarding the action taken by the clinician, 23% (no=47) repeated the analytics, 20% (no=40) adjusted the medication, 12% (no=24) contacted the patient and 9 %( no=19) sent the patient to the emergency service. 30% (no=63) no actions were taken by the clinician or they are unknown because they are not shown in the clinical history.
Conclusions
In view of our results, we consider that our protocol is useful because, thanks to it and to the rapport between the laboratory and the clinical services, we have been able to resolve situations that endanger the patients' lives.
We are surprised by the fact that in sixty-three patients no action was taken or it was not shown in their clinical histories. We objectify that approximately half of them were admitted patients with glucose and/or potassium alterations, on whom the action was probably limited to clinical observation.
From the laboratory we plan to update our protocol by conducting consensus surveys with the clinicians, with the aim of continuing to improve the quality of care. 
Background-aim
Quality in laboratory has a big impact on diagnosis and patient management as 80-90 % of all diagnosis is made on the basis of laboratory tests. The identification of reliable quality indicators is a crucial step enabling users to quantify the quality of laboratory services. The ISO15189 mandates the implementation of quality indicators. In this study we evaluated the performance of the laboratory through some set of quality indicators. Sigma value depicts the performance of laboratory and its quality measures. Hence in the present study six sigma principle was applied to the quality indicators to evaluate the clinical biochemistry laboratory performance.
Methods
The present study was conducted in the Department of Biochemistry at Medanta-The Medicity Hospital from January 2015 till December 2016. The quality indicators (QI) for the pre-analytical phase were sample rejection rate (SRR) which included number of clotted specimen, haemolysed sample, insufficient sample, wrong tube/label and diluted sample. For analytical phase the indicators were concordant proficiency testing (CPT), equipment uptime and repeat testing. Turnaround time (TAT) compliance and critical alert callout were included for the post-analytical phase. The trend was observed for all QI for the two years. Data was collected into an excel file for analysis and % performance compared over both the years. SRR and TAT were evaluated with the sigma scale.
Results
A total of 1,414,244 (6, 90,751 in 2015 and 7, 23,493 in 2016) specimens were received for testing. In 2015, 6564 (0.95%) specimens were rejected giving a sigma level for SRR of 3.90. Sample dilution was the most common pre-analytical error with a sigma value of 4.2. Whereas in 2016, 4716 (0.65%) samples were rejected giving a sigma level of 4.00 with haemolysed sample being the common error giving a sigma value of 4.4. There was an improvement in proficiency testing from 97.7 % in 2015 to 99 % in 2016. Equipment uptime also showed a significant improvement from 91.1 % in 2015 to 96.8% in 2016. No. of samples for repeat testing however increased from 0.30 % in 2015 to 0.40 % in 2016. A total of 80,554 (0.95%) samples were not meeting TAT in 2015 with a sigma level of 2.70. Whereas 42,158 samples (0.65%) were reported to not meet the TAT in 2016 giving a sigma level of 3.10. For the critical values communicated to inpatients within one hour an improvement from 97.8 % in 2015 to 98.9 % in 2016 was observed.
Conclusions
The results of our study indicate a general improvement for most of the QIs. Most significant improvement was found in the pre-and post-analytical phase due to sensitisation of staff which included training events and issue of informative documents to decrease error of request data input. The use of quality indicators to assess and monitor the quality system of the laboratory is an important tool to assure the improving process and guarantee the patient safety. 
Background-aim
Contemporary quality control (QC) design focuses on minimizing the risk of patient harm. Following new expectations we reviewed the QC strategy for our 23 clinical chemistry tests.
Methods
We have been using independent controls (Bio-Rad) for years. QC results are evaluated using the Unity software (Bio-Rad). The Westgard Advisor of Unity was used to select the QC rules for each test. Since there is no national total allowable error (TEa) recommendation in Hungary, therefore the biological variability (BV) data was used for TEa. BV minimum bias and imprecision was chosen as default settings. Since September 2018, we have been able to test Bio-Rad's new Mission:Control (MC) software version 2, which makes recommendations for the frequency of QC and calculates the patient's risk assessment.
Results
In the case of tests with Sigma N4 (16 tests), the risk management index (RMI) was b1, which means a controlled risk. The initial settings did not need to be changed in terms of QC rule and QC frequency according to MC. But for tests with Sigma b4 (7 tests), RMI was N1. For instance in the case of total protein the default setting resulted in RMI 4.03 (TEa: 5.45%, Sigma: 2.48, 1 daily QC, repeat 1:2s rule, 50 samples per day, severity of harm: minor, probability of harm: 50%). As a results of changes suggested by MC (3 QC per day, 1:2s rule), RMI decreased to 3.8. Leaving all other settings unchanged and increasing TEa to 6% (Rilibak recommendation) Sigma was 2.82 and RMI was 1.59. Based on MC suggestion (3 QC per day, 1:2s rule), RMI was reduced to 1.48. Increasing TEa to 8% (SEKK recommendation), Sigma and RMI became 4.06 and 0.09 respectively. Following the CLIA recommendation (TEa: 10%), Sigma and RMI changed to 5.3 and b0.001 respectively. In the latter two cases, there was no need for further action.
Conclusions
There are 2 to 11-fold differences between the loosest and the tightest TEa values in the various recommendations. In 6 out of 7 tests, the default TEa (BV minimum bias and imprecision) was the lowest of the optional values. Consequently the well-chosen TEa had a greater impact on RMI than QC frequency or QC rules. 
Background-aim
Medical laboratory is integral to many clinical decisions on prevention, diagnosis, treatment and management of patient disease. Therefore, the quality of laboratory services is paramount. One of important factors that influence a laboratory's overall activity is support of policy makers. An assessment of the national laboratory system in Mongolia will help to identify its strengths and gaps.
Methods
The questionnaire-based assessment of strategic organization and support at the national level (e.g. defining policies and regulatory framework) was performed with participation of members of the Laboratory professional council of the Ministry of Health of Mongolia (MOH), MOH officers in charge of diagnosis and reference services, and officers in charge of monitoring and assessment of health servicesь and their answers were substantiated with related documents. The assessment results were generated and analyzed using an Excel questionnaire program, and scores below the 75% limit were considered insufficient.
Results
The findings of the laboratory system assessment show that the strongest areas of the country's laboratory system at the policy and regulatory level are "Coordination and management" and "Laboratory information system". The laboratory-related coordination at the Ministry of Health is well established and functional, and the national laboratory data collection and analysis activity is centralized and is implemented by the Center of Health Development of MOH. Gaps are found in "Infrastructure", "Regulations" and "Human resources". The poor result of "Infrastructure" is due to financial shortcomings. The main problems detected in the area of "Human resources" include insufficient financial and organizational support for the continuous education of laboratory workers, a shortage of trained personnel and incomplete national registration system of laboratory professionals. 
Background-aim
Accurate test results enable health professionals to make the right diagnostic and therapeutic decisions. In order to demonstrate the quality and reliability of their services, medical laboratories seek accreditation to ISO 15189. There are more than 300 medical laboratories in Mongolia, and only seven are accredited so far. We have initiated a project to assist medical laboratories in their efforts to obtain the accreditation. As a first step of the project activity, we carried out a gap analysis of laboratories.
Methods
Six laboratories representing private and public, urban and rural medical laboratories are selected for participation in the project. The gap analysis of the participant laboratories is carried out using an Excel program that incorporates all ISO 15189 requirements.
Results
The findings reveal that the participant laboratories are strongest in the following categories: Organization and management, Quality of examination results, Personnel and facility management and Laboratory information management. The majority of the laboratories are hospital based, and their organization and management are well established and functional mostly due to centralized administrative guidance. The concept of quality control is effectively adapted in medical laboratories, and data management is usually in line with the requirements. Weaker areas include Evaluation and audits, and Document control. Even though the laboratories do conduct evaluations and control, they do not do it regularly and, most importantly, do not keep records routinely, which cause the higher gap rate.
Conclusions
Policies to meet ISO 15189 requirements are in place in the participant laboratories, but their documentation and records keeping are insufficient. doi:10.1016/j.cca.2019.03.1067
M315
Design and implementation of quality control plans that integrate moving average and internal quality control: Incorporating the best of both worlds
H. Van Rossum, D. Van Den Broek
The Netherlands Cancer Institute, The Netherlands
Background-aim
New moving average quality control (MA QC) optimization methods have been developed and are available for laboratories. Having these methods will require a strategy to integrate MA QC and routine internal QC.
Methods
MA QC was considered only when the performance of internal QC was limited. A flowchart was applied to determine, per test, whether MA QC should be considered. Next, MA QC was examined using MA Generator (www.huvaros.com), and optimized MA QC procedures and corresponding MA validation charts were obtained. When a relevant systematic error was detectable within an average daily run, the MA QC was added to the QC plan. For further implementation of MA QC for continuous QC, MA QC management software was configured based on earlier proposed requirements. Also, protocols for MA QC alarm work-up were designed to allow detection of temporary assay failure based on previously described experiences.
Results
Based on the flowchart, 10 chemistry, 2 immunochemistry and 6 hematological tests were considered for MA QC. After obtaining optimal MA QC settings and the corresponding MA validation charts, the MA QC of albumin, bicarbonate, calcium, chloride, creatinine, glucose, magnesium, potassium, sodium, total protein, hematocrit, hemoglobin, MCH, MCHC, MCV and platelets were added to the QC plans.
Conclusions
The presented method allows the design and implementation of QC plans integrating MA QC for continuous QC when internal QC has limited performance. 
Background-aim
Safety and hygiene are among the priorities of any medical analysis laboratory, they are an integral part of any quality process, including the ISO 15189 qualification, it is an obligation in the framework of the Moroccan regulation. The quality of performance of a medical analysis laboratory is based on the control of its organization and its processes. the neglect of security may cost a lot to the laboratory : its reputation, the health of the staff and the patients, the quality of the results, the biomedical material invested, as well as the hygiene of the environment.
Methods
Initially, we began by structuring the risk management approach using the 5M method, from which we extracted the main risk factors for adverse effects. We identified them and calculated the criticality of each by FMEA method, then we prioritized them by a farmer diagram and we finalized our work with a plan of corrective and preventive actions based on a collective brainstorming and experience other biomedical laboratories in managing these risks.
Results
The main risks identified were biological risk, chemical risk, physical risk, fire risk and environmental risk. Prevention measures for some of these risks were almost non-existent, while for others the risk was unavoidable. Our action plan was based on this prospective identification and we started by highlighting the critical risks first, by initiating a prevention procedure based on the single document and the moroccan regulations in the field of security.
Conclusions
The laboratory remains a sector with a wide variety of occupational exposures and the assessment of occupational risks in the face of these hazards is a regulatory obligation that everyone must invest in. doi:10.1016/j.cca.2019.03.1069
M317
Evaluation of the effect of more frequent reporting in analytical performance through the use of an international external quality assessment scheme S. Doherty, G. Kansanaho, M. Rodríguez, L. Adams, S. Fitzgerald Randox Laboratories Ltd., Crumlin, United Kingdom
Background-aim
To ensure reliable reporting of patient test results, the periodical assessment of the analytical performance of the laboratories through External Quality Assessment (EQA) schemes is relevant. An EQA scheme allows comparison of results of participant laboratories by their methodology, instrument and reagent, which facilitates the identification of potential failures and inter-laboratory agreement to ensure the test system accuracy needed to meet regulatory requirements. Frequent reporting allows early identification of system errors and implementation of any necessary corrective actions with minimum disruption to the laboratory. In this study the EQA scheme, Randox International Quality Assessment Scheme (RIQAS), was used to evaluate how the frequency in the reporting affects performance of clinical chemistry parameters
Methods
General Clinical Chemistry Programme samples (52 parameters) were assessed by participants either every 2 weeks or every month depending on their chosen frequency option. The performance indicators, %Deviation from the mean for comparison (%Dev) and the Target Deviation for Performance Assessment (TDPA) were studied. TDPA is a target %deviation which represents the lowest average 10% of the most poorly performing participants, for any given parameter, averaged over 1 year. The differences between TDPA on bi-weekly and monthly frequencies were compared. The parameter lipase was studied in detail to establish reasons for the differences.
Results
For the majority of parameters (50 out of 52), the TDPAs for 2017 for samples assessed bi-weekly were smaller than for samples assessed monthly. For lipase, the biweekly TDPA was 10.2%, while the monthly TDPA was 21.3%. The average % deviation of lipase for samples assessed biweekly was 1.56% (n = 12463) while the % deviation for samples assessed monthly was 4.94% (n = 17791). Other factors such as age of the samples, length of time of participation in the programme, location of participants, method and instrument did not have significant impact in the reported trend
Conclusions
The results from this report indicate a trend in the improvement of the analytical performance by increasing the frequency of reporting in the EQA RIQAS. 
Background-aim
Sepsis is, the most severe manifestation of acute infection, can cause multi-organ failure and ends in death in 30-50% of cases. Blood cultures (BC) are considered the most sensitive method for detecting bacteremia and are commonly obtained in patients with fever, chills, leukocytosis, focal infections and sepsis. Short blood culture turnaround time (BC-TAT) can improve adequacy of antibiotic treatment and prevent unnecessary and superfluous empiric treatment To achieve BC-TAT reduction, improve patient outcomes and reduce unnecessary antibiotic consumption.
Methods
The study was conducted at Rambam Health Care Campus, Israel. The microbiology laboratory (micro-lab) operates between 07:00-20:00. On July 2016, an intervention was implemented to allow BC processing 24/7, through collaboration between the microbiological and STAT laboratories, computer and infectious disease divisions and the hospital administration. Outside the micro-lab working hours, BC are transferred to the STAT laboratory and are incubated in a satellite incubator (Bactec FX-40, BD, USA), connected to the microbiological laboratory information system (LIS). At the beginning of each working day, the bottles are transferred to the main incubator (Bactec FX, BD, USA) at the micro-lab for continued processing. A hospital-wide education campaign was launched to encourage BC delivery to the relevant lab 24/7 immediately after BC drawing.
Results
The time from BC drawing to its arrival to the laboratory during nighttime decreased by 82% from 6.8 hours to 1.2 hours. During the 2-year period of the intervention, 642/15540 cultures, representing 4.1% of total cultures handling in the STAT laboratory, were signaled as positive in the STAT laboratory, allowing immediate processing at the micro-lab in the morning. BC-TAT, calculated as the time from arrival to the micro-lab or STAT lab until results were reported to the physician, were improved by 12% for positive and 4.5% for negative BCs.
Conclusions
Our results demonstrate that collaboration between different clinical laboratories can improve processes. Our next objective is to examine the effects of the intervention on clinical outcomes and antibiotic consumption. 
Background-aim
The STA Satellite Max is a new bench top analyzer designed to perform in vitro tests for the diagnosis and monitoring of disorders related to hemostasis. It is meant for routine labs with small hemostasis activity or can be used as back-up instrument in larger organizations. It performs clotting, colorimetric and turbidimetric assays.
Our laboratory was the first European center to evaluate this new instrument and assess its ergonomics along with reliability and some analytical performances, under a routine-like setting of tests.
Methods
Over 3 weeks, our lab had to test at least 30 patients' samples on STA Satellite Max each day, along with intra-assay reproducibility and cross contamination evaluations, using citrated plasma samples from patients.
Reproducibility was assessed over 10 replicate measurements on prothrombin time (PT), activated partial thrombin time (APTT), fibrinogen (Fib), antithrombin (AT) and d-dimer (DDi) levels, using STA-NeoPTimal 10, STA-Cephascreen 4, STA-Liquid Fib, STA-Stachrom ATIII 3 and STA-Liatest DDi respectively.
Cross contamination was evaluated by comparison of mean results of 10 APTT tests measured in a raw versus 10 APTT tests measured in combination with PT tests.
Results
No major issue appeared when using the analyzer, during the routine testing of patients' samples.
Intra-assay CVs obtained were of 1.49%, 0.25%, 2.57%, 1.96% and 2.79% for PT (sec), APTT (sec), Fib (sec), AT (%) and DDi (μg/mL) respectively.
Relative deviation of mean APTT during cross contamination assessment was of 0.83%.
All those results easily meet acceptance criteria.
Conclusions
STA Satellite Max shows good reproducibility and cross contamination results. Easy-going for work and reliable on the tests evaluated, the instrument can be used in the hemostasis clinical laboratory. Calprotectin is a calcium and zinc binding protein implicated in the regulation of the inflammatory process that represents about 60% of soluble proteins of granulocytes cytoplasm.
Faecal Calprotectin (FC) is an evidence-based medicine biomarker to diagnose IBD with a high sensitivity that can reduce unnecessary invasive colonoscopies due to its ability to differentiate organic from functional IBD. It is recommended to apply a grey zone between 50 and 200 μg/g and levels N200 μg/g are indicative of active organic IBD.
Methods
We analysed the number of FC requests in our Hospital during the last 5 years. Then we selected the patients that were suspected or suffered from IBD and the ones that were not suspected to have IBD, excluding the requests without diagnose, and we stratified them by FC levels: b50 μg/g, 50-200 μg/g and N200 μg/g.
Results
We registered 10003 FC requests from January of 2013 until September of 2018 (2013: 29, 2014: 483, 2015: 1425, 2016: 2341, 2017: 3179 and from January until September of 2018: 2549).
The sample of patients that were suspected or suffer from IBD was formed by 3434 patients: 27% (911) FC b 50 μg/g, 25% (871) FC 50-200 μg/g and 48% (1652) FC N 200 μg/g. On the other hand, 2872 patients were not suspected to have IBD: 50% (1427) FC b 50 μg/g, 28% (800) FC 50-200 μg/g and 22% (645) FC N 200 μg/g.
Conclusions
FC request has increased exponentially because it is not an invasive method, its cheap to perform and it has a high sensitivity.
Moreover, a 48% of the patients that were suspected or suffer from IBD have and active organic disease and a 25% are in the grey zone. Otherwise, just a 22% of patients that were not suspected to have IBD have an active organic disease and 28% are in the grey zone. In order to that we should consider applying a demand management to FC request. 
Background-aim
We recently shifted from conventional troponin I (c trop I) assay to high sensitive troponin I (hs trop I) assay on Alinity i by Abbott Diagnostics. Alinity i system has recently been launched internationally, and we are among the first ones in Pakistan to adopt the assay on this analyzer. Our objective was to to verify the performance characteristics of hs trop I on two Alinity i analyzers.
Methods
Precision: This was verified by running commercial controls at three different levels in five replicates for five days.
Accuracy: External proficiency sample were run and results compared to Architect group mean.
Sensitivity: Limit of Blank, Limit of Detection and Limit of Quantification were determined and compared to vendor claims.
Method comparison: 40 samples were analyzed for c trop I on Vitros ECi and hs trop I on both Alinity I analyzers across entire analytical measuring range (AMR).
Verification of 99th percentile URL: Hs trop I was performed on 40 healthy male voluntary blood donors (20 on the each Alinity i). HbA1c and estimated creatinine clearance of the donors were also determined to further define normality.
Results
Precision study showed a precision of 5.6/5.7, 1.4/2.7 and 1.1/4.1 for Alinity i 1 and 2 at low, medium and high levels. The samples were within total allowable error in the CAP proficiency testing survey when compared to Architect series, though with a negative bias. Limit of blank was 0.93 and 0.27 ng/L and limit of detection was 1.7 and 0.7 ng/L on Alinity I 1 and 2 respectively. Limit of quantification was verified to be less than 5.1 ng/L as claimed (3.6 and 4.4 ng/L).The assay demonstrated a CV of less than 6% at 99th percentile URL on both Alinity i. Passing Bablock between c trop I on VItros ECi and hs trop i on the two Alinity i instruments showed a slope of 0.988 (r = 0.99)and 0.921 (r = 0.96), (95% CI included 1.0) with a negative intercept of 3.98 and 3.35, and no significant difference in mean concentrations. Hs trop I levels were below the gender specific cut offs in all healthy donors, being undetectable in 35 out of 40 tested so far. It needs to be seen if 99th percentile URL levels are lower in our ethnic group.
Conclusions
The performance characteristics of hs troponin I assay are verified on Alinity i. 
Background-aim
Alinity series was recently launched internationally with great fanfare. We are among the first in Pakistan to install Accelerator a3600 and Alinity ci series as part of Total Laboratory Automation. Initial studies published on Alinity ci have been carried out in Abbott laboratories. Independent data is needed to verify manufacturer's claims. We aimed to verify performance specifications (precision, accuracy, linearity and reportable range) of common quantitative clinical chemistry and immunoassay parameters on two Alinity c and i systems as per CLSI guidelines. Method verification studies are the exceptions rather than the rule in our part of the world.
Methods
The method performance was verified on two Alinity i analyzers.
• Simple and Complex Precision: These were determined by running commercial controls at three different levels in five replicates for five days. Mean, standard deviations and coefficient of variation were determined, and compared with the company claims. • Accuracy: 3-7 proficiency testing samples of various levels were tested in 3 replicates and results compared with Architect group mean. • Linearity/ Reportable Range: 7 levels spanning analytical measuring range of parameters not having multi point calibrators were run in 3 replicates. Mean values at each level were compared to target values to see if they were within total allowable error. Recovery and linearity were calculated. • Sigma metrics: Sigma metrics for the assays were calculated from accuracy and precision (TAE-bias/CV).
Results
In all 27 clinical chemistry, and 13 immunoassay analytes were tested. All clinical chemistry and immunoassay parameters met manufacturer's claims for precision, accuracy, linearity and reportable range on both Alinity c and i systems. In all 87.5 % of assays were at greater than 5 and 6 sigma levels. CO2, Chloride and Free T4 were between 4 and 5 sigma, while sodium and Free T3 were between 3 and 4 sigma.
Conclusions
Abbott's claims for precision and accuracy were verified. In all 87.5 % of the assays evaluated were at more than 5 and 6 sigma.
Limitations of the study:
• 
Background-aim
Incognizant of Resolution AFR/RC58/R2 (2008) and Maputo Declaration that emphasizes the strengthening of laboratory system, the top management in LCRH resolved to implement and bolster this noble course by enrolling LCRH laboratory in Strengthening Laboratory Toward Accreditation (SLMTA) process. Since 2015, the top-level management through the office of the director zealously committed itself to successfully compete at the international level of performance. It knew without management commitment, laboratory involvement and practice, the effort would be stymied and abortive. This study is aimed at demystifying the massive support the management has accorded the laboratory for continual and sustainable improvement.
Methods
Before the SLMTA process commenced in LCRH, the management was brought on board and sensitized about the entire process by the experts with an aim of fostering commitment and buy-in. This was fundamental in enlightening the management on how the process will provide a controlled and efficient high level of technical competence and quality service to its customers. All the departmental heads that were directly or indirectly linked to the laboratory were involved which included but not limited to Nursing head, clinician, laboratory staff, and maintenance staff-towards the mission of sustainable quality practices.
Results
The Laboratory moved from zero to five stars in a period of three years. Currently earmarked for accreditation. There was an overhaul renovation, extension, and reorganization of laboratory floor plan for optimal workflow. Equipment was put on the service contract and a reduced equipment downtime from 30% to 2% due to controlled temperature and periodic preventive maintenance. The management engaged in resource mobilization and advocacy which increased staff level from 8 to 15, participation in external quality assurance schemes, a budget for commodities, training and mentorship. A 
Background-aim
Khoo Teck Puat Hospital is a 626 bed Acute Care hospital that employs multi-skilled technologists to run the core laboratory during the night shift (2100h to 0900h the next day). During this shift, one medical technologist manages both the Blood Transfusion Services (BTS) and Cerebrospinal Fluid (CSF) analysis. Upon monthly review of CSF Turn Around Times (TAT), there was a consistent and distinct prolonging of TAT during this shift. The two hour Key Performance Indicator for CSF TAT was prolonged to as much as 300 minutes for 12.4% of the total daily workload compared to 63.6% of the night workload.
Methods
Data on the total number of samples received and the TAT for the tests performed by technologists in a 24-hour cycle was collected from the Laboratory Information System for a period of one month. We used Lean methodology and Quality Improvement tools to identify the various contributors and potential root causes. A relationship map was plotted over 24 hours incorporating Blood Transfusion and CSF workloads, their respective TATs and manpower allocation.
Results
There were 129 requests for CSF and 1019 requests for Blood Typing and Antibody screen during this period. Of the 1019 antibody screens performed, 981 subsequently required Antibody identification (ABID). The average daily TAT for CSF was 130 minutes (n = 129, SD 76 mins). The CSF TATs for day and night shifts were 111 minutes (n = 120; SD 63 mins) and 164 minutes (n = 11; SD 90 mins), respectively. During three periods of prolonged CSF TAT during the night, there were 17, 52 and 61 cases of ABID in the BTS versus 1, 2 and 3 cases of CSF at the same time. This correlated with a CSF TAT of 262, 300 and 246 minutes, respectively.
Conclusions
Our analysis showed a relationship between BTS workload, long CSF TAT and manpower. During periods where a single technologist was on duty and the BTS workload was high, the TAT for CSF was prolonged. Our root cause analysis and value stream maps showed that workload numbers provide superficial information but a deep dive into test complexity showed involvement to prolonged TAT. These tools can also be used to imply a future state that can meet the intended service level by process improvements and optimisation that will result in a faster diagnosis and improved patient outcome. 
Background-aim
The anti-Müllerian hormone (AMH) is an established biomarker for assessing ovarian reserve; consequently, it requires accurate AMH measurements. The strategy of internal quality control to assure analytical performance can be assessed by in-kit (IK) controls, supplied by the manufacturer or by third party (TP) controls, unaffiliated to the reagents and calibrators used in the measurement. Therefore, TP controls have distinct advantages; they can detect a shift due to degradation of the calibration materials and avoid releasing erroneous patient results.
The aim of this study is to compare the ability of an IK to a TP control in order to detect possible changes in instrument performance.
Methods
PreciControl AMH Plus (IK) (Roche) is a lyophilized equine serum matrix in two concentrations ranges. The new Liquichek AMH Control (TP) (BioRad) is a liquid serum of human origin, in three concentrations ranges. Both controls were stored in aliquots of 150 μL at − 20°C. Materials were processed over a period of 2 months, two days a week by duplicate (n = 22), using one reagent lot and two different calibrations, on the cobas e411 analyzer (electrochemiluminescence ECLIA). Statistical analysis was performed using Microsoft Excel.
Results
The assigned values of the two levels of control materials for IK and TP were 0.76 ng/mL vs 0.95 ng/mL and 4.64 ng/mL vs 4.56 ng/mL respectively.
The imprecision (coefficients of variation) obtained were 7,58% and 3,28% for the IK, while TP controls showed lower results 2,35% and 3,06%.
The IK control presented a bias of −5.12% at low level and 2.84% at high level. A bias of −2.65% and −3.86% were obtained in both levels of TP control respectively.
Conclusions
Both control materials presented adequate assigned values concentrations, which monitor assay performance at different medical decision levels. TP appears to be more stable than the IK, probably due to its liquid stable presentation that minimize pipetting error. Both materials showed a negative bias in the concentration near to the clinical decision level used for assessing the ovarian reserve, being less noticed in the TP control, maybe due to its human origin. The new Liquichek AMH Control (TP) of BioRad can be an adequate alternative to monitor the measurement of AMH. doi:10.1016/j.cca.2019.03.1078
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Making the switch from high performance liquid chromatography (HPLC) to capillary electrophoresis (CE)-The Edinburgh experience P. Ryan NHS Lothian, Livingston, United Kingdom
Background-aim
The haemoglobinopathy laboratory at the Royal Infirmary of Edinburgh provides a screening service for the South East of Scotland, testing approximately 4000 patient samples annually. Historically the service has been provided using high performance liquid chromatography (HPLC), however the department has recently changed to capillary electrophoresis (CE).
The change to CE was driven by several factors: the current contract with the HPLC supplier was due to expire, an increased awareness of the need for a contingency due to ISO15189 requirements and the need to future-proof against possible workload rises.
There were several barriers to overcome in changing methods. The primary barriers related to resistance to change within technical, scientific and medical staff groups, however there were also logistical barriers e.g. installation/maintenance, procurement/financial issues and IT integration.
Methods
A CAPILLARYS 2 FLEX PIERCING instrument was provided by Sebia on loan, allowing laboratory staff to become familiar with use of the equipment and interpretation of the results. A period of evaluation was carried out over 4 months where all samples received for HPLC screening were also tested by CE. Over this period, over 1500 samples were tested, providing results covering common variant haemoglobin traits and several variations of disease states.
Results
The CE results agreed with the HPLC results, providing confidence in the method.
Logistical barriers were also addressed through this loan instrument, as technical difficulties encountered during the evaluation period were resolved, providing reassurance in the service provided. Sebia had confirmed the loan instrument would be the analyser permanently used, meaning installation and validation requirements had been met.
Procurement proved to be problematic and time consuming, delaying the implementation of CE by several months.
The final roadblock was that of IT interfacing and validation, which required a good deal of planning and organisation to ensure "go-live" was successful. This resulted in a further delay in switching over to reporting via CE, however the transition occurred in May 2018.
Conclusions
The transition between technologies was smooth, with no significant issues encountered. 
Background-aim
The use of traditional quality control in hematology testing with use of the commercial control blood has several drawbacks: expenses, problems with appropriate storage, stored material may slowly deteriorate even if maintained in an appropriate manner, the short shelf life, the inter-vial variability.
In addition, the control blood is the material that consist of stabilized red blood cells, latex particles instead of white blood cells, animal platelets and other cells and particles. So it is very far from the real patient's blood. Recently, there has been renewed an interest in quality control algorithms using patient samples: moving average (MA) algorithm.
In our laboratory, the MA algorithm is being implemented in addition to the use of the commercial control blood.
Methods
Samples (sp) of patients with EDTA received from the hospital departments. Exclusion criteria: age b 12 and N 86 years, patients with hematology disorders and under chemotherapy.
The study of blood (EDTA) of patients was carried out on the hematological analyzer CELL-DYN Ruby (Abbott Diagnostics). For daily quality control used control blood CBC-3K (R&D Systems) and a standard set of rules Westgard.
Measurements of leukocyte count (WBC), erythrocyte (Er), platelet (Plt) and hemoglobin concentration (Hgb) were chosen as a model.
Results
Based on the available capabilities for the calculation of MA, an approach was chosen with direct calculation of the sample average and truncation limits, corresponding to the reference intervals of WBC, Er, Plt, Hgb.
At the first stage, we retrospectively estimated the average value of hematological tests for our patient population (WBC -13 059 sp, Plt -15 347 sp, Er -14 031 sp, Hgb -11 801 sp), for HGB and Er additionally with sex stratification (male -4 473 sp and 6 091 sp; female -7 328 sp and 7 940 sp respectively).
Further, on the basis of the obtained averages, operational control charts (MA-chart) were built. The accuracy requirements were the same as for the control blood charts (LJ-chart). Daily mean values of patients with appropriate inclusion criteria and results within reference intervals were calculated. Daily average number of patients is: WBC, Plt -80-100; Er, HGB male -30 -40, Er, Hgb female -50 -60.
MA-chart analyzed together LJ-chart for decision-making about the correctness of the obtained results of hematological analysis.
Conclusions
The following preliminary conclusions were drawn:
• Long-term CV can be calculated from MA-chart data.
• MA-chart allows to detect lot to lot variability of reagents, which is impossible for the control blood due to the short shelf life. 
Methods
Lyophilized human sera samples, prepared from repeated pools were sent to participating laboratories for monthly process. 46 analytes were included in the group: Cholesterol, Glucose, Creatinine, Bilirubin, Uric acid, Amylase, CPK, AST, ALT, Calcium, Magnesium, Iron, LDH, ALP, Proteins, Sodium, Potassium, Triglycerides, GGT, Urea, Albumin, HDL, TSH, FT4, T3, T4, FSH, LH, Estradiol, Cortisol, Testosterone, Progesterone (P4), Insulin, Prolactin, Ferritin, PSA, CEA, IgE, HCG, AFP, Ca125, CA15-3 Ca19-9, 17-OHprogesterone, SDHEA, Androstenedione (AD). For performance comparison through time, we considered yearly 50% percentile (pCV50%) average laboratory imprecision and its corresponding 50% percentile average bias (pB50%).
Results
Mean group imprecision decreased 41.9% except for P4 that increased 36.4%. Mean group bias decreased 45.9%, except for Ca19-9 that increased 114%, P4 41%, AD 28% and SDHEA 12%. Major difference was observed in insulin, pCV50% and pB50% decreased 72% and 73% respectively.
Conclusions
Measurement quality improved both in imprecision and harmonization; this can be attributed to advances in technology and platforms, clinical guidelines and laboratory quality awareness. Clinical chemistry analytes, which have traceability to international reference standards, demonstrate greater harmonization than immunoassays in general. P4 performance may be due to introduction of new assay design by a major method. Increase in pB50% for Ca 19-9 and SDHEA may be attributed to one major method, not harmonized with the rest. For AD, an important difference between automated and manual methods increased pB50%. Laboratory performance evolution helped to achieve more reliable and reproducible results having a positive impact on patient safety. 
Background-aim
The Laboratory accreditation verifies laboratories have an appropriate Quality Management System (QMS). International Standard (ISO) by ISO 15189 has been applied in clinical laboratories in many areas like biochemistry, immunology, pathology and microbiology. In flow cytometry, recently there are more laboratories in the need of implementing these quality systems but is not easy because flow cytometry is a very flexible technique in which it is not easy to find standardization in the use of the reagents, protocols, instruments and even criteria of acquisition of the events of each sample.
Our objective is explain our experience in the implementation of standard 15189 in the study of T lymphocyte subpopulations and in the study of HLA-B27 and the challenges we had to overcome to obtain and renew the quality system.
Methods
For the quality control of the cytometers we use CS&T beads (BD) and for the cytometer calibration 7 Color Setup Beads (BD). For the acquisition and the analysis, we use BD FACSCanto Software and the reagents Multitest CD3/CD8/CD45/CD4 and HLA-B27 Kit (BD). We had to participate in external quality controls (EQC) and to use internal controls (Multicheck CD4 and CD4 Low multicheck) using Two 8 Color flow cytometers (BD FACSCanto II). We needed to perform the validation test of the method, as well as records of equipment maintenance, incidents, improvement actions, personnel training, Standard Operating Procedures, equipment and program manuals, technical data sheet, and more information such as external documentation, degrees of compliance and verification of internal controls.
Results
We obtained accreditation UNE-EN ISO15189 by the National Accreditation Entity with the following scope: Name Description CD4 % Percentage of T CD4 T lymphocytes CD4 lymphocytes Absolute counts of T CD4 cells (cells/mm3) CD8% Percentage of CD8 T lymphocytes CD8 lymphocytes Absolute counts of T CD8 cells (cells/mm3) CD3 % Percentage of CD3 T lymphocytes CD3 lymphocytes Absolute counts of T CD3 cells (cells/mm3) CD4/CD8 Ratio CD4/CD8 HLA-B27 HLA-B27
Conclusions
We obtained the ISO 15189 accreditation for the proposed achievements but we had to deal with some obstacles like the absent of internal control for the study of HLA-B27. The implementation of ISO 15189 has been useful to work correctly and a way according to the established standards, but also for the control of risks. The next challenge is to accredit the ISO 15189 in hematological pathologies, for which we will need greater standardization in the procedures (preanalytical, analytical and reporting) and the obtaining of EQC that allow us to perform an adequate intercomparing to the concrete pathology that we want to accredit. For this purpose, Euroflow system could be useful since it has standard procedures for the processing of samples, calibration and analysis described in detail. 
Methods
A retrospective descriptive study of the determinations made during six consecutive months has been carried out, the data have been obtained from Modulab (Werfen), our laboratory information system (LIS). The determination of CRP was performed in an Architect c16000 system (Abbott) by immunoturbidimetry and the determination of PCT in a Cobas E411 system (Roche) by chemiluminescent immunoassay (ECLIA).
Results
In the period of the study, 11,080 requests with CRP and PCT were requested and jointly determined. 14.8% (1,640) of these, had a CRP result b5 mg/L, 21.8% (2.418) CRP b10 mg/L, 26.8% (2,972) CRP b15, 31,3% (3,466) CRP b20 mg/L and 34.7% (3,842) CRP b25 mg/L. 89.9% of the patients with CRP b5 had a negative value of PCT (b0.5 ng/mL), 90.3% with CRP b10, 89.6% with CRP b15, 88.8% with CRP b20 and 87.5% with CRP b25.
PCT was positive in patients with CRP b5 in 10.1% of cases, with CRP b10,9.7%, CRP b15, 10.7%, CRP b20, 11.3%, and CRP b 25 12.5%.
If a filter is established in order not to perform the PCT determination (unless there is a high clinical suspicion) depending on the level of CRP, it is estimated that it could mean an annual saving of 26240 euros (CRP b5), 38688 euros with CRP b10), 42624 euros with CRP b15), 55456 euros with CRP b20) and 61472 euros with CRP b25).
Conclusions
With CRP cut-off points b5, b10 and b15 mg / L, similar results are obtained (in %), being the CRP point b10 with which we obtain the best results (90.3% of negative PCT).
When the CRP value increases (b15, b20 and b25), the data gets worst, which, in our opinion, we do not recommend to base the filter on CRP values higher than 10 mg/L.
We believe that the lowest impact for patients (9.7% of PCTN 0.5 ng / mL) is achieved using a CRP value b10 with a substantial annual saving (direct cost 38.688 euros), since the number of determinations that are saved is much higher than the cut-off point CRP b5 and that difference is not maintained with the CRP cut b15.
We must remark that this protocol would be a base to start working and to which other parameters such as the number of leukocytes could be added and always recommending the determination when there is a high clinical suspicion. Continuous variables were expressed as mean ± standard deviation (SD), median (minimum-maximum values) and categorical variables as number and percent. Shapiro-Wilk tests were used for testing normality. We used kappa analysis to evaluate agreement between gold standard and HPLC and IA measurements. Sensitivity, Specificity, Negative and Positive predictive values were used f to analyze the performance of HPLC and IA measurements. Wilcoxon signed rank test was used for determining the difference between gold standard values and other technics. Venn diagrams were used to examine consistency between 3 methods. All statistical analyses analysed by SPSS, 24.0 and p-value less than 0.05 was considered statistically significant.
Results
We accepted deficiency/insufficiency/sufficiency/toxic levels respectively 0-10& 10-20& 20-70&N70 (ng/ml) those were defined by World Health Organization (WHO). Patients' age means value was the 50.2±17.69 year. D vitamin mean values 21.2±14.49 nmol/L, HPLC was 22.72±14.83 nmol/L and IA 19.45±14.73 nmol/L. There was strong accordance among three-assay method. As a gold standard method LC-MS/MS, sensitivity, specificity, positive and negative predictive values for HPLC and IA were respectively 88.9-93.3%, 94.3-82.9%, 95.2-87.5%, and 86.8-90.6%.
Conclusions
In deficiency clinic, IA more compatible then HPLC with the gold standard. HPLC was successful in insufficiency than the IA method. In the present study Abbott 25-OH-Vitamin D assay is appropriate for determining Vitamin D status. Background-aim CHU de Bordeaux is a large teaching hospital in France with a robust, decentralized POC testing (POCT) program. Management of decentralized blood gas testing across a network of acute care settings and a vast number of operators (more than 800) requires a rigorous quality framework, close partnership between the lab and clinical areas and reliable technology to ensure success.
This analysis describes the management of 12 GEM® Premier™ 4000 and implementation of 7 new GEM Premier 5000 blood gas analyzers networked to GEMweb® Plus 500 Custom Connectivity (Instrumentation Laboratory) in acute care settings across two hospital sites using ISO 22870 framework.
Methods
Three dedicated lab technicians supported the roll-out of the new blood gas analyzers using ISO 22870 framework to meet the clinical and quality requirements of each area throughout the pre-installation, validation and go-live phases. The process required a close and constant partnership between the laboratory, clinical care services, biomedical staff, material management, suppliers and many other stakeholders. Pre-planning included: definition of requirements, compliance, connectivity, patient records, method validations, document management, competency training, and consumables, among others. All phases of the roll-out examined key quality indicators to measure success.
Results
The 7 new GEM Premier 5000 analyzers were added to the network in less than 6 months, with a carefully executed quality plan. Over 495 care staff in 10 sectors were trained as a part of the program. Management and implementation of the new systems were facilitated by the built-in risk management features of the GEM Premier 5000 with iQM2 and GEMweb Plus, specifically as it pertained to quality management (including COFRAC reports), error detection, device management and operator competency training.
Conclusions
Implementation and management of a broad blood gas program requires rigorous quality standards, processes and technology. Active collaboration of the main clinical and laboratory stakeholders in a decentralized roll-out is fundamental. GEM Premier analyzers tied into GEMweb Plus can be effective tools to facilitate accreditation compliance and decentralized testing management, particularly as it pertains to risk-management requirements. 
Background-aim
To evaluate the automated QC feature of Alinity ci system (Abbott Laboratories) and its benefits in laboratory operations.
Methods
A Sigma metric study was carried out on 4 immunoassays and 7 clinical chemistry assays to compare automated QC mode with manual QC using Technopath multiconstituent control materials. Sigma metric values were calculated based on 5-day precision and the bias of the mean values against target values to assess the quality of QC results. In the automated QC mode, controls were pipetted and tested directly from the onboard control vials. The control lot number, target values and range were read by the instrument from the barcode of the vials. In the manual QC mode, controls were manually pipetted into sample cups prior to testing in each run. A manual input of the control lot number, target values and range was also required. The performances of precision, sigma metrics and turnaround time were evaluated on both QC modes. The turnaround time was determined as the cumulative time of the QC procedure from the QC material preparation through QC test completion.
Results
The precision and sigma metrics resulting from automated QC are comparable with those from manual QC mode. The within-laboratory precision for the 7 assays ranged from 0.52% to 3.95% CV for automated QC and from 0.41% to 3.31% CV for manual QC. Ninetyone percent of the assays tested on the automated QC mode (or 10 out of 11) and 82% on the manual QC mode (or 9 out of 11) were found to be operating at 5 Sigma or above. Time savings of 22.3% were achieved by using the automated QC mode as compared with manual QC.
Conclusions
While the precision and Sigma-metrics performances were comparable between the automated and manual QC modes, the automated QC feature of Alinity ci System enables the saving of time in daily QC procedure and increase of walkaway time, leading to a reduced labor requirement, improved turnaround time and enhanced operational productivity. 
Background-aim
The pre-analytical phase is the most critical in the clinical laboratory. Around 70% of errors occur, affecting significantly to the safety of the patient. The aim of our study was to establish a system of management of the pre-analytics incidents and check if we comply with the quality specifications given by the SEQC in 2017.
Methods
Computer tests representing the following incidences were created: erroneous identification, not received serum samples, not received urine samples, inadequate serum samples, and hemolyzed sample.
The specifications were established: He was carried out in the full year 2018, and quarterly way of seven primary care centers attends to our laboratory. Was Compared with the specifications given by the SEQC in 2017.
Results
The results were satisfactory. Specifications 1, 2, 3 and 5, came to desirable in all primary care centres during the four quarters of the year. Specifications 4 and 6 remained within levels minimum and several centers in 1 or 2 quarters were above. Instead those related to urine (7 and 8) had in all health centres and in several quarters a level above the minimum. It is a primary care centre with the best indicators, all of them at desirable levels and optimal except in the urine in two quarters.
Conclusions
We think that a better tool is very useful for extraction points, for this reason the clinical laboratory implement an annual report to each centre with its results, high lighting the strengths and suggesting actions of continuous improvement as the management of samples of urine in this case, and we will continue measuring these indicators as management of pre-analytical phase. 
Background-aim
Laboratory tests adequacy is a key element towards quality of medical laboratory outcomes, in terms of patient safety, efficiency and effectiveness. Several studies revealed high test request variability and a significant test over request. The aim of the present work is to assess the impact of a demand management strategy for anemia parameters in the context of primary care.
Methods
A multidisciplinary group was created for the evidence medicine protocols revision and algorithm elaboration. The algorithm was introduced thanks to the laboratory information system middleware. The experience was piloted in three primary care centers prior to total implantation.
Results
The algorithm designed condition biochemical anemia parameters to hemoglobin and medium corpuscular volume (MCV) results. If no anemia is evidenced, no further investigation is made. If anemia is evidenced, according to MVC result different test are completed: iron and ferritin (b80 fL), vitamin B12 and folic acid (N98 fL) or iron, ferritin, lactate dehydrogenase and reticulocyte count (80-98 fL). The results of the strategy application were the decrease of the anemia parameters as follows: iron 43% (CI: 34-51), ferritin 42% (CI: 33-51), transferrin 92% (CI 91-94), vitamin B12 66% (CI 53-79) and folic acid 70% (59-82%)
Conclusions
Mayor decrease was obtained for transferrin, vitamin B12 and folic acid. Transferrin was inadequate used for iron deficiency anemia. Vitamin B12 and folic acid were wrongly demanded for no anemic and/or microcytic anemias.
The impact of test over request is minimized due to the applied algorithm, patient safety is not compromised and an improvement of resources was achieved. 
Background-aim
During this study, we analyzed two aspectsreagent-and waste handlingthat are of high relevance for everyday organization in diagnostic laboratories.
We compared six commercially available immunochemistry analysers, with respect to cooled space required to store reagents and their production of solid infectious waste.
Methods
The comparative evaluation was performed at two laboratories in Germany and Spain on analyzers from five different manufacturers: two cobas e 801 analytical modules (Roche Diagnostics), ARCHITECT i2000SR (Abbott), UniCel DxI 800 (Beckman Coulter), Liaison® XL (DiaSorin), ADVIA Centaur XPT and IMMULITE 2000 XPi (Siemens Healthineers).
Demands for cooled storage space were determined for typical clinical laboratory assays on basis of the respective manufacturer's reagent packaging. Our analysis included a total of 18 assays (Ferritin, PTH, Estradiol, FSH, beta-HCG, LH, Progesterone, Prolactin, Testosterone, AFP, CA 125, CA 15-3, CA 19-9, CEA, fPSA, tPSA, free T4, TSH) covering reagents from five indication areas.
The production of potentially infectious solid waste was evaluated by processing standardized hospital /commercial laboratory like workloads on each analyser and determining the weight of the solid waste output. In addition, the solid waste production per determination including that contributed by the empty reagent packs was calculated per system.
Results
The cooled storage space requirement for the test panel differed significantly among the included analysers. Total storage volumes (L) ranged from 79L (cobas e 801 system) up to 925L (Immulite 2000 XPi) for an identical number of determinations including calibrators.
The amount of potentially infectious solid waste ranged between 0.6g (cobas e 801 system) per determination up to 2.8g (ADVIA Centaur XPT).
Considering the solid waste contributed by empty reagent packs per determination and identical workloads representing both commercial and hospital like workloads, a waste reduction of up to 77.5% was observed on the cobas e 801 system in comparison to ADVIA Centaur XPT.
Conclusions
Our study provides laboratory managers with comparative cooled storage space and solid waste data over various commercially available immunochemistry systems. 
Background-aim
The latest update of the ISO 15189 accreditation standard requires that laboratories know and estimate the uncertainty of the results provided by their measurement systems.
This metrological concept is taking a huge interest in clinical biochemistry, but it is still quite unknown in the haematology field.
The aim of this study is to estimate the measurement uncertainty of seven haematological quantities results measured in Sysmex XN analyzers (Roche Diagnostics®).
Methods
The quantities evaluated were: number concentration of erythrocytes (RBC), reticulocytes (RET), leukocytes (WBC) and platelets (PLT-I for impedance and PLT-F for fluorescence method), mass concentration of haemoglobin (HB) and volume fraction of erythrocytes (HTO).
Expanded measurement uncertainty (U) was estimated for nine Sysmex XN analyzers. For each quantity and analyzer, the following formula was applied:
2√(u cal^2 +u p^2 +u δ^2 ), being:
1. u cal : uncertainty associated with the values assigned to the calibration material (XN CAL PF for PLT-F and XN CAL for the rest of quantities). 2. u p :uncertainty associated with imprecision expressed as coefficient of variation (CV), obtained by measuring XN CHECK Level L2 controls during a period of 4 months. 3. u δ :uncertainty related to the bias of the measured system. The formula applied was √(™^2+u x^2 +u μ^2 ) , being ™ the bias, u x uncertainty associated to the mean value of the control results, and u μ uncertainty corresponding to the value assigned to the control material. All data were obtained from the external quality scheme assessment SNCS-IQAS Online.
Since control lot changes every two months, weighted data from two different lots were employed to estimate u p and u δ .
Finally, in order to obtain a single uncertainly value for each quantity, a weighted U for the nine analyzers was calculated.
Results
The weighted U obtained for each quantity was: 3.53% for RBC, 2.80% for HB, 6.43% for HTO, 8.07% for WBC, 12.33% for PLT-F and 19.45% for RET.
Conclusions
Uncertainty allows quantifying the quality of the result and evaluating its reliability, providing a correct clinical interpretation of it. This study could help and motivate clinical laboratories to perform uncertainty studies in the haematology field. 
Background-aim
Thyroid disease is common in most people. It is important to compare the patient's thyroid function test results with reference intervals(RIs) derived from a matched population. Ideally, each laboratory should determine RIs based on representative studies of the target population. However, to establish RIs using traditional method is difficult to perform, time-consuming, costly, and often inaccurate. In light of these difficulties, most laboratories elect not to establish their own RIs, but rather choose to verify manufacturer's RIs which may be established in different countries and do not necessarily apply to the local population. Some alternative methods have been suggested and include the use of outpatient population instead of healthy volunteers. The aim of this study was to estimate RIs for T3 and T4 using matched clinical population.
Methods
We employed a posteriori study, so-called indirect method, where results from specimens were collected for routine clinical care purposes and used to determine the RIs. Thyroid function test (TSH, free T4, T3, and T4) results were measured using two Roche Cobas e601 analyzers and over one and a half years period (Jan. 2017~Jun. 2018) were retrieved from our 531-bed regional hospital outpatient electronic medical record system to constitute the original database for this study. The division of metabolism and endocrinology outpatients were excluded. For each T3 and T4 test, the presence of both TSH and free T4 tests without any abnormality were included to assure normal thyroid status. The RIs were estimated the central 95% range of the population by a nonparametric method using EP Evaluator software.
Results
Original T3 and T4 manufacturer's RIs were 84.6~201.8 (ng/dL) and 5.1~14.1 (ug/dL). The newly implemented T3 and T4 RIs we established from our own hospital outpatients were 50.9~142.1 (n = 1772) and 4.6~9.7 (n = 499) respectively and successfully verified by the conventional approach with 20 healthy volunteers.
Conclusions
This study showed the "indirect method" for RIs estimate is suitable, faster, cheaper, and can provide large patient numbers for more robust assessment for laboratories use the manufacturer's RI derived from unmatched population there is a need to establish a new RI. doi:10.1016/j.cca.2019.03.1091
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Three-years of experience of accuracy-based lipid proficiency testing service in Korea
J. Kim Yonsei University College of Medicine, South Korea
Background-aim
Accuracy-Based Lipids (ABL) Proficiency Testing (PT) program started from 2016 by Korean External Quality Assessment Service (KEQAS) to minimize matrix effect. We present the three-years of experience of ABL PT.
Methods
We made six kinds of commutable frozen sera according to the CLSI 37A guideline and distribute in two rounds every year from 2016 to 2018. We got the reference values of total cholesterol (TC), HDL cholesterol (HDLC), LDL cholesterols (LDLC) of each fresh frozen pool from the reference measurement laboratories, CEQAL, the one of the cholesterol reference measurement laboratory network laboratory and total glycerides and free glycerol reference values by isotope dilution gas chromatography mass spectrometry from National Medical Reference Laboratory (NMRL) in Korea Center for Disease Control and Chemical Metrology Laboratory, Health Sciences Authority (HAS) in Singapore or ReCCS in Japan, respectively. We evaluate the average %bias of participating laboratories according to National Cholesterol Education Program (NCEP) bias limit.
Results
The number of participating laboratories of TC, HDLC, LDLC, Total glycerides, and Triglycerides were increased from 164 to 223, 163 to 223, 158 to 214, 98 to 139, and 61 to 82, respectively. The average %bias (consensus vs. reference values) of all participating laboratories for TC, HDLC, LDLC, Total glycerides, and Triglycerides were +0.14%, −0.54%, +2.9%, −1.08%, and −1.32%, respectively. Although the average %bias or absolute %bias showed within the bias limit of NCEP, the exceeding cases of bias limit sometimes occurred. The average % bias of LDLC showed exceeded NCEP bias limit most frequently (8 out of 18 pools). Instrument-specific bias estimation report seemed to stimulate each manufacturer to keeping traceability.
Conclusions
Although the average %bias of participating laboratories for TC, HDLC, LDLC, Total glycerides, and Triglycerides showed within the bias limit of NCEP, the exceeding cases of bias limit sometimes occurred especially in LDLC during recent 3 years in Korea and ABL PT can be useful to keeping traceability not worrying about matrix effect. 
Background-aim
The Working Group for Preanalytical Phase in Latin American (WG-PRE-LATAM) of the Latin America Confederation of Clinical Biochemistry (COLABIOCLI) was established in 2017, and its main purpose is: to study preanalytical variability and to establish guidelines for preanalytical procedures in order to be used by clinical laboratories and healthcare professionals in Latin America. This study on behalf of COLABIOCLI WG-PRE-LATAM aiming at evaluating whether an Ecuadorian breakfast can interfere with thyroid function assays.
Methods
We studied 20 healthy volunteers who consumed an Ecuadorian breakfast containing a standardized amount of carbohydrates, proteins, and lipids. We collected blood specimens for thyroid stimulating hormone (TSH), and free thyroxine (fT4) before the breakfast and 1, 2, and 4 hours thereafter. Significant differences between samples were assessed by the Wilcoxon ranked-pairs test.
Results
The Ecuadorian breakfast impressively decrease thyroid stimulating hormone (TSH) 1 hour after breakfast vs. baseline specimen 1.33 mIU/mL (0.90 -1.83) vs. 1.82 mIU/mL (1.03 -2.21), respectively; P b 0.001. Free thyroxine (fT4) decreased 7.1% four hours after Ecuadorian breakfast 12.7 pmol/L (11.6 -14.4) vs. 13.6 pmol/L (12.1 -15.7), respectively; P = 0.014.
Conclusions
Findings of this study reveal that an Ecuadorian breakfast can influence the thyroid function assays and might expose patient safety to some risks. Therefore, the COLABIOCLI WG-PRE-LATAM calls attention and highlights that the fasting time needs to be carefully considered when performing blood testing in order to prevent spurious results and thus, reduce laboratory errors. 
Background-aim
Clinical laboratories have been working on quality for more than 50 years. In all this time, the technologies have improved and the analytical quality has reached a level of excellence in most clinical laboratories, the non-analytical quality focused on the processes and workflows (Lean) has begun to work no longer more than 10 years A new methodology that was born in the area of software development and that is very useful for the empowerment, leadership and commitment of the work teams (Lean Agile) has been working for less than 5 years in the area of Health. This methodology is based on a series of activities that seek to improve the value delivered to the client focused on a human factor. There are a series of tools that can be used in agile methodologies, among them is SCRUM, Kanban, Extreme programing. For this study, Management 3.0 created by Jurgen Appelo was used. This is a series of concrete practices that help inspire managers and team members with the idea of generating positive change in the organization. The objective of this study is to determine the contribution of Management 3.0 in the management applied to Clinical Laboratories.
Methods
A series of meetings was organized with the directors of 5 different clinical laboratories in Santiago of Chili to determine the type of Management 3.0 activity to be carried out with the laboratory staff, teams of 4 to 7 people were created with which they worked once a week in sessions of no more than two hours. According to the objectives set, we worked on Mental Map activities, Moving Motivators, Delegation Poker and Skills Matrix. The results of each of these activities were placed in the office of the director of the clinical laboratory in order to visualize what was working.
Results
A week after the first activities planned with the work teams, important changes were observed in the work environment, improved communication flow between people and allowed to advance in a better way with the following planned activities. Once these activities that took about a month were completed, a series of actions were implemented that improved the flow of information among the staff, who participated in the activities were more committed and motivated to do new Management 3.0 activities and generated an interest of the rest of the staff to know and participate in any of the activities carried out
Conclusions
Lean Agile helps make changes in the organization in a short time. The activities carried out in Management 3.0 allow adding value to the product generating a change in the work environment that allows to do the activities in a better way, in a shorter time at a low cost. Workers who can make decisions and trust them are more committed and empowered workers in their daily activities. 
Background-aim
The aim of this study was to assess the impact on our laboratory workflows of the introduction of a completely automated analyser (Interlab G26 EasyFix) for performing serum and urine immunofixation (s-IFE and u-IFE).
Methods
This assessment required the prior identification of some Key Point Indicators (KPIs) and their comparison against the preceding adopted solution (the semi-automated Hydrasys analyser in conjunction with the Assist sampler). The following KPIs have been identified: Turn Around Time (TAT), Full Time Equivalent (FTE), Average Walk Away time, number of interventions by the operator, involved personnel, number of installed instruments. The study of the workflows has been performed by using Gantt diagrams. The related results refer to a typical 8 hours working day during which an average of 4 s-IFEs and 16 u-IFEs are performed.
Results
The following results have been obtained respectively on the Interlab and on the Sebia systems: TAT (6h 8' Vs 6h 16'), FTE (0,03 Vs 0,07), Average Walk Away Time (1h 23' Vs 6'), number of operator interventions (4 Vs 28), involved personnel (1 technician + 1 validator Vs 2 technicians + 1 validator)number of installed instruments (1 Vs 2). The Interlab analyser allowed to significantly improve the FTE (by 57%), the Average walk Time (by 13 times) and the number of operator interventions (by 600%). It shall be noted that the number of installed instruments (1 Vs 2) has been reduced, as well as the operator dedicated time.
Conclusions
At equal analytical and diagnostic performances, the INTERLAB G26 EasyFix instrument, by representing an all-in-one solution, has proved its capacity to optimize the workflows in the clinical laboratories while guaranteeing the full automation and traceability of samples, antisera and gels. Furthermore, the significant improvement of technical FTE and of the involved personnel allowed to estimate a reduction of costs, relieving human resources that can be allocated to other laboratory sectors. The Interlab G26 system results, therefore, to be a valid alternative to the SEBIA system for performing second level tests aimed at immunologically characterising the serum and urine monoclonal components (s-IFEs and u-IFEs). 
Background-aim
The aim was to present the Failure Modes and Effects Analysis (FMEA) risk analysis tool for planning the reagent water(RW) quality control in the clinical lab to improve cost reduction and patient safety.This is a critical process and an error-prone,based on the severity of possible harmful events may cause a potential dangerous impact to the patient.
Methods
The FMEA in this process involved:a multidisciplinary team; collecting and organizing information on the process;risk analysis; identifying failures modes for each step;determining the potential effect of each failure mode; ranking the severity of failure mode effects(S); ranking the probability of occurrences(O) and detection capacity(D) of each failure mode. The risk priority score(RPS) was calculated by multiplying S*D*O considering:RPSδ40 acceptable and/ or residual risk and RPSN40 means high risk. Identifying and prioritizing the critical failures modes. Implementing actions through the Quality Control Plan (QCP), covering all uses of RW in the laboratory.New evaluation was made after the action plans were completed.
Results
The RW process was mapped and the risks were analyzed for each step. The RPS (pre and post) was calculated. The QCP generated was defined with the following topics: training for staff; daily resistivity measurement; weekly microbiological control of water (heterotrophic bacteria); monthly control (endotoxins and total organic compounds);control of particulate matter filtration/the type of water; preventive maintenance of the purification system (PS); calibration of manometer, resistivimeter and thermometer; control of pre-filters of the PS; traceability of the filters; cleaning of the water tank (1/year); redundancy of PS; contingency plan; criteria of acceptance/ type of reagent water.
Conclusions
The risk evaluation for planning and control RW helps to reduce the occurrence of adverse events in the clinical laboratory. The reliability of RW in the lab depends on the risks identified and evaluated so that the QCP is appropriate to the needs, prevents errors by the use of the RW and can avoid waste. FMEA and QCP brought more quality to RW, reducing errors and costs, increasing the effectiveness of the process and patient safety. 
Background-aim
Ascorbic acid (AA) interference causes falsely negative glucose (U-Glc), blood (U-Hb), nitrite (U-Nit) and bilirubin (U-Bil) results in urine test strip analysis. Our aim was to determine the frequency of AA positive urine samples submitted for analysis to our department and to evaluate their effect on patient safety.
Methods
Results from N = 27,856 samples submitted to our laboratory for urinalysis in one year were retrospectively retrieved from the laboratory information system (LIS). Samples were collected using VACUETTE® TUBEs Z Urine No Additive (Greiner Bio-One, Kremsmuenster, Austria) and analysed on the Iris IQ200 (Iris Diagnostics, Chatsworth, USA). iChem Velocity test strips (Iris Diagnostics, Chatsworth, USA) were used for U-Glc, U-Hb, U-Nit , U-Bil and AA determination. Risk analysis combined the impact of erroneous results (due to AA interference) on patient safety (severity-S) with their frequency (occurrence-O). Risk was identified as high, intermediate and low.
Results
Negative AA results were detected in 25,012 (89.8%) urine samples, while 1199 (4.3%) and 1646 (5.9%) were mildly (20 mg/ dL, 1+) and highly positive (40 mg/dL, 2+), respectively. We identified 4 possible errors: false negative U-Glc, U-Hb, U-Nit and U-Bil. Five S classes were identified ranging from the lowest harm S1 to the highest S5 (i.e. S1 for U-Bil, S2 for U-Glc, S4 for U-Nit and S5 for U-Hb). Based on LIS results, O was categorized as O1b3%, O2=3-10%, O3=10-25%, O4=25-50%, O5N50%. Accordingly, errors were classified as O2 for U-Glc, and O3 for U-Bil, U-Nit and U-Hb. The risk analysis 5×5 matrix revealed that false negative U-Hb was associated with high risk, false negative U-Nit with intermediate risk, while false negative U-Glc and U-Bil were associated with low risk on patient safety.
Conclusions
The frequency of AA positive urine samples submitted for analysis was quite high in our study. Furthermore, AA interference with U-Hb and U-Nit analysis causing false negative results, is associated with higher risk of harmful effects on patient safety. AA test strip analysis should be routinely included in urinalysis protocols and AA results should be taken into account when interpreting urinalysis test results. 
Background-aim
Ortho Clinical Diagnostics (Ortho) has developed the new VITROS® XT 7600 Integrated System (VITROS XT 7600) which utilizes digital chemistry technology to support the new VITROS XT Chemistry Products Slides (XT MicroSlides). The XT MicroSlides with dual test capability are intended to reduce sample size and enhance operational efficiency while maintaining analytical performance versus the conventional single slide test. Digital chemistry technology enables the use of imaging algorithms to improve chemistry results, such as within-lab precision. This study will examine withinlab precision, comparing the VITROS XT 7600 with digital chemistry capability versus the VITROS 5600 Integrated System (VITROS 5600) with traditional spectrophotometry.
Methods
The precision of six XT MicroSlides: UREA-CREA Slides, ALTV-AST Slides*, TRIG-CHOL Slides*, ALB-TP Slides*, GLU-Ca Slides*, and TBIL-ALKP Slides* for two serum concentrations was evaluated using quality control materials on a VITROS XT 7600. Total within-lab precision (reported as percent coefficient of variance) for a single calibration was evaluated with two runs per day with two replicates per run over 20 days, for a total of 80 replicates following CLSI EP05 guidelines.
In addition, customer quality control precision data from single test slides from VITROS 5600s were extracted and evaluated. The customer quality control data points were screened for statistical outliers and outliers were removed. The %CV was calculated for each lot/fluid/system combination and compared to the within-lab precision for the XT MicroSlides on the VITROS XT 7600.
Results
The within-lab precision for VITROS XT MicroSlides on the VITROS XT 7600 was compared to the corresponding single test slides within lab precision on the VITROS 5600. The XT MicroSlides lots reported within-lab precision as improved or equal for 19 out of 24 examined assay/fluid combinations. The exceptions being CHOL* at PV1 (1.9% vs. 1.5%); CREA at PV2 (1.6% vs. 1.4%); TBIL* at PV1 (3.8% vs. 3.1%); ALTV* at PV1 (2.4% vs. 1.9%); and ALTV* at PV2 (1.7% vs. 1.4%).
Conclusions
The data presented here demonstrate that the new XT Micro-Slides using new imaging algorithms provide comparable or improved precision relative to single test slides from internal and external precision studies. 
Background-aim
High homocysteine (Hcy) levels have been observed in thromboembolic diseases, psychiatric (schizophrenia, depression) and neurodegenerative (Parkinson's disease, Alzheimer's disease) pathologies, showing a potential role of Alzheimer's in the pathogenesis of these disorders, hence the importance of developing Hcy assay techniques in our laboratory. The objective of this study was to validate the method of enzymatic plasma quantification Hcy on Cobas 6000 c502® Roche Diagnostics™ and to compare the results obtained by our method on neurology patients with those obtained by liquid chromatography tandem mass spectrometry (LC-MSMS).
Methods
The Hcy Enzymatic Assay (Hcy-EA) is based on an enzyme cycling assay principle that assesses the co-substrate conversion product. The validation parameters such as repeatability, intermediaire precision, accuracy, quantification limits as well as linearity and measurement uncertainty were evaluated using internal and external quality controls. The results obtained by our method and those by the LC-MSMS technique on 30 patients were compared. The statistical data are processed by the SHGTA-04 (SPSS software) with Ricos objectives.
Results
The repeatability and reproducibility study on Hcy concentrations at 12 and 40 ⎧mol / L showed coefficients of variation respectively b1.5% and b2%. Accuracy and precision were consistent with the objectives. The linearity covered a range of 50 ⎧mol/L and quantification limit was 5.5 ⎧mol/L. A result of Hcy at 12 is made +/-0.5 ⎧mol/L. The statistical analysis of the patient results allowed to show a correlation (r: 0.988, p b0.0001) and a strong agreement between the two assay techniques. The results obtained by the Cobas are overestimated by 20% compared to those obtained by LC-MSMS, highlighting the need to change the threshold of normality and clinical decision-making currently defined for LC-MSMS from 10 ⎧mol/L to 12 ⎧mol/L for Hcy-EA.
Conclusions
The validated Roche Diagnostics™ enzymatic plasma Cobas 6000 c502® Hcy-EA method demonstrated good performance in quantifying plasma Hcy levels. The concordant results obtained in this study allow us to realise Hcy-EA at Meaux and a resumption of an outsourcing activity for a better follow-up of neurology patients. 
Data analysis has determined that the Sigma value for selecting Quality Indicators pre-analytical, analytical and post-analytical processes meets the predefined criteria. Monitoring of Quality Indicators is used for self-assessment of a Medical-Biochemistry Laboratory. 
Background-aim
Identification and quantification of monoclonal component (MC) in serum and urine (Bence Jones protein, BJP) by electrophoresis and immunofixation, are included in clinical protocols for patients with monoclonal gammopathies (MG); however, the sensitivity of these techniques may not be sufficient when MC levels are low.
Since 2001, main clinical practice guidelines recommend quantification of serum free light chains (FLCs) due to its higher analytical sensitivity as well as diagnostic and prognostic value, while maintaining the recommendations regarding BJP studies.
Aims
To assess the concordance between results derived from serum FLCs quantification and urine BJP studies.
Methods
Two years-long retrospective study in which 499 patients with clinical suspicion of MG were included. For the entire cohort, urine BJP studies and serum FLCs values [Kappa, Lambda and Kappa/ Lambda ratio (rFLC)] were collected.
Urine proteinograms and immunofixations were analyzed by capillary electrophoresis (Capillarys, Sebia), and agarose gel electrophoresis (Hidrasys, Sebia), respectively. FLCs were quantified by nephelometry (Freelite®, Binding Site).
Statistical analysis was carried out with MedCalc software (v. 13.0). Chi-squared test was applied to evaluate the concordance between BJP and FLCs results, both rFLC alone and the combined evaluation (CE) of serum FLCs (Kappa, Lambda and rFLC), and p b 0,05 was considered as statistically significant.
Results
Comparision of BJP results with rFLC showed that rFLC was abnormal in 24,2% patients, while no monoclonal band (MB) was identified in urine, probably due to the lack of sensitivity described for BJP. On the other hand, for 7,2% patients a urine MB was identified in the presence of a normal rFLC, likely because of the polyclonal nature of FLCs. When comparison was made with the CE, similar results were observed: 36,4% of patients showed some CE disturbance in the absence of a MB in urine. These differences were statistically significant. Conversely, none of the patients with normal CE showed a urine MB.
Conclusions
In those cases in which serum FLCs are within the established reference values, BJP analysis in urine does not provide additional information to the diagnosis or follow-up of MG. 
Background-aim
Laboratories have to face to an increasing demand of workload combined with a reduction of resources.
Implementing strategies to reduce the use of unnecessary and redundant tests is an important tool to manage increasing health care costs.
We observed that there were laboratory reports that were not visualized by clinicians at the Emergency Department (ED) of a tertiary level hospital.
Aim: evaluate the number of laboratory requests at the ED that were not visualized by any clinician.
Methods
Retrospective observational unicentric study, between May 4 and June 21, 2018. We use the Computerized Laboratory Information Management System to get the information of total number of analytics, and a report of non-visualized episode´s number.
Data was processed by a Microsoft Excel database and statistically treated in SPSS programme.
Results
There were 46,287 analytical requests made to emergency laboratory, 10,434 from the ED (Children´s and General Hospital), 175 not visualized by clinicians (1.7%). 52 (29.7%) were registered in the morning shift, 80 (45.7%) in the afternoon and 43 (24.6%) in the night.
The age distribution was b1 year 0.6%, 1-15 years 10.8%, 16-65 65.2%, N65 23.4%; and the analytical priority normal 94.9%, urgent 1.1% and vital 4%.
58.3% of requests had hemogram, 56.0% biochemical tests, 57.1% coagulation tests, 41.7% urinalysis, 4.6% troponin I and 1.7% D dimer.
Patient´s destination after discharge from emergency service was home in 67.4%, voluntary discharge 9.2%, transfer to another hospital 1.7%, hospital admission 15.4 %, and death 0.6 %.
The potential explanation for non-visualizing the reports were: duplicated requests (more than 1 request for the same patient) 14.9%, referral to another specialist doctor 22.9%, voluntary discharge 9.2%, visualization of wrong report 4.6%, results not used for patient diagnosis 47.5%, death 0.6%.
Conclusions
The not visualized reports mean performing an invasive technique that it will not contribute to benefit the patient nor will be used in a clinical decision, that may impact on patient care. It is necessary to monitor this performance indicator and communicate/ discuss these results with the ED to optimize laboratory tests. Background-aim BD Barricor tubes are plasma blood collection tubes with mechanical separator. We aimed to test if these tubes are superior to BD Li-heparin gel tubes and can be used intermittently in the laboratory.
Methods
Verification was conducted in Clinical Hospital Centre Rijeka from February till April 2017. The samples were taken from out-patients who signed informed consent. Tubes were randomized by the order of draw. Blood was taken in BD Li-heparin gel tube and BD Barricor tube. Analyses were done 2-4 h after blood collection. Verification protocol was adopted from CLSI GP34-A Validation and verification of tubes for venous and capillary blood specimen collection. All samples were visually inspected and tested on Roche Cobas 6000 (Roche, Mannheim, Germany) for: glucose (GLU), urea (BUN), creatinine (CRE), cholesterol (CHOL), total proteins (TP), AST, LDH, CRP, sodium (Na), potassium (K), chloride (Cl) and calcium (Ca). We accessed precision (CV), trueness (bias), and comparison of measurements by Passing-Bablok analysis using MedCalc (MedCalc, Ostend, Belgium). Precision and trueness (bias) were judged according to the biological criteria. 
Results
CV (%) for BD Barricor and BD
Conclusions
All tubes showed good quality based on visual inspection. CV and Bias of BD Barricor tubes are satisfactory. We used broader criteria for CRE, Na, Cl and Ca. Electrolyte comparison mismatch occurred because of the limitation of the analytical performance. BD Barricor tubes are not superior when compared to BD Li-heparin gel tubes for tested parameters. doi:10.1016/j.cca.2019.03.1103
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Use of within-and between-subject biological variation data for analytical performance specification in external quality assurance scheme: A retrospective study A. Terreni, G. Avveduto, P. Pezzati, Q. Massimo SOD Sicurezza e Qualità, CRRVEQ, Dipartimento dei Servizi, AOU Careggi, Florence, Italy
Background-aim
External Quality Assurance (EQA) schemes providers evaluate laboratory performances based on analytical performance specification (APS). Presently, Providers establish and applies APS using different criteria. The 1st EFLM Strategic Conference held in Milan in 2014, defined three models to be used to derive APS: based on the effect of analytical performance on the clinical outcome (M1); based on components of biological variation (BV) of the measurand (M2); based on the state of art of the measurement (M3). Plasmatic Na, K, Cl, and Total Protein were assigned to M2. Chemistry EQA scheme results, we showed the following percentages of laboratory meeting respectively optimal, desirable and minimum goal: Na 20%, 38%, 50%; K 70%,92%, 95%; Cl 22%, 45%, 60%; plasma protein 50%, 80%, 91%. When TEA derived from Ricos et al. were used, we showed : Na 18%, 33%, 47%; K 78%, 95%, 100%; Cl 26%, 53%, 68%; Total protein 54%, 80%, 92%. The CRRVEQ, similarly to several international providers, adopts ASP based on a combination of BV and state of the art, and, as expected, the percentage of laboratories evaluated as having positive performances was higher: Na 88% ; K 92% and 95% ( K b3.0 mmol/L and N3.0 mmol/L respectively); Cl 92% and 85% ( b90 mmol/L and N90 mmol/L respectively); Total Protein 92% and 89% (b5.0 gr/dL and N5.0 gr/dL respectively).
Methods
Since
Conclusions
We can affirm that, mainly for Na and Cl, the APS based on BV may represent a difficult goal to achieve for the majority of laboratories. doi:10.1016/j.cca.2019.03.1104
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Performance of hormone assays in EQAS "Buenos Aires" ProgBa -Cemic 
Methods
Home-made materials (12 lyophilized human sera prepared out from different pools) were sent to participant laboratories. Target values were assigned as consensus mean for each peer group and between-laboratory CV% was calculated; acceptance limits were stated as +3SD. Performance statistics for individual laboratories were calculated through annual cumulative results: performance index PI was computed as meanCV% and meanBIAS%; PIs were ranked and calculation of percentiles p25, p50, p70 and p90 defined bands from very good to unacceptable (A B C D E 
Results
We calculated % labs in different performance groups (A+B acceptable, C regular, D+E bad) in each method. Acceptable performance for major methods was: COBAS ROCHE: TSH 62% n = 85, FT4 66% n = 84, LH 65% n = 76, FSH 66% n = 75, PRL 46% n = 75, hCG 63% n = 72, E2 74% n = 76, To 75% n = 66, P4 41% n = 62, CSOL 61% n = 61; ABBOTT ARCHITECT: TSH 41% n = 36, FT4 21% n = 34, LH 21% n = 28, FSH 86% n = 28, PRL 87% n = 31, hCG 77% n = 31, E2 43% n = 30, To 38% n = 21, P4 96% n = 25, CSOL 46% n = 24; ACCESS BECKMAN: TSH 54% n = 11, FT4 45% n = 11, LH 29 % n = 7, FSH 17% n = 6, PRL 50% n = 6, hCG 14% n = 7, E2 0 % n = 9, To 13% n = 8, P4 0% n = 9, CSOL 72% n = 7; CENTAUR SIEMENS: TSH 50% n=35, FT4 50% n=20, LH 42% n=17, FSH 17% n=6, PRL 81% n=16, hCG 0% n=12, E2 38% n = 8, To 0% n = 8, P4 71% n = 7, CSOL 25% n = 12; IMMULITE SIEMENS TSH 29% n = 35, FT4 45% n = 33, LH 40% n = 25, FSH 0% n = 28, PRL 6% n = 30, hCG 22% n = 32, E2 19% n = 19, To 0% n = 11, P4 43% n = 19, CSOL 35% n = 15.
Conclusions
Differences in acceptable performance and mean CV% were found for all hormones, reflecting different laboratory implementation and robustness of platforms. EQAS is a useful tool for follow up of method performance, as results reflect the state of the art in hormone assays. Traceability as claimed by manufacturers did not lead to acceptable harmonization in some of the hormones, as reflected in differences in mean BIAS%. doi:10.1016/j.cca.2019.03.1105
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Determination of sigma score based on biological variation for haemostasis assays: Fit-for-purpose for daily practice?
Background-aim
Internal quality control (QC) rules for laboratory tests can be derived from analytical performance specifications (APS) using the six-sigma method. We tested the applicability of this paradigm to routine haemostasis measurements.
Methods
Three laboratories using different instruments and reagents calculated sigma scores for their prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen and antithrombin (AT) measurements. Sigma scores were calculated using biological variation (BV) data from the literature in combination with internal and external QC data. Internal data were derived from one quality sample in the normal range collected in three consecutive months and external data were based on 6 external quality surveys with 2-3 data points per survey.
Results
Wide ranges in sigma scores for the PT (0.1-6.8), APTT (0.0-4.3), fibrinogen (1.5-8.3) and AT (0.1-2.4) were observed when QC data was combined with the minimum, median and maximum value of BV data, due in particular to a large variation in within-subject and between-subjects coefficients of variation. When the median BV values were applied, most sigma scores were below 3.0, for internal QC data; 75% and for external QC data; 92%.
Conclusions
Our findings demonstrate that: 1) The sigma scores for common haemostasis parameters are relatively low and 2) The application of the six-sigma method to BV-derived APS is hampered by the large variation in published BV data. An updated database is needed, in which only BV studies are included which fulfil standardised criteria. Since the six-sigma concept is based on requirements for monitoring, and many haemostasis tests are only designed for diagnostic purposes, a fit-for-purpose APS is needed to achieve clinically relevant quality goals. 
Background-aim
Rapid and safe rule out of acute myocardial infarction in patients admitted to emergency department (negative predictive value N99%) can be achieved by setting limit of blank (LOB) or limit of detection (LOD) of highly sensitive cardiac troponin assays (hsTn) as decision thresholds. Accurate calibration of hsTn in the low concentration range is therefore of the upmost importance for this application.
Even relatively small analytical variations may indeed influence the proportion of patients who could be identified as suitable for discharge. To monitor baseline drifts and calibration accuracy at very low hsTn concentrations, in March 2017 we introduced a serum pool with a concentration between LOB and LOD as an additional internal quality control material (IQC3). Here we show the impact of this additional quality tool on EQAS performance.
Methods
In our laboratory, we measure hsTnT on two interchangeable Roche Cobas e411 platforms (LOB and LOD: 3 and 5 ng/L, respectively) and participate to the UK-NEQAS, which includes a low concentration sample (LCS) in each monthly exercise. We evaluate EQAS results according to an allowable total error (TEa) of ±22.5% (biological variability derived) between our result and the mean of participants using the same measuring system. The IQC3 is prepared from fresh leftover human sera with hsTnT concentrations between 3 and 5 ng/L and stored at -20°C in 250-μL aliquots. IQC3 target value and acceptability range are preliminarily determined by calculating mean ± 30% of 10 measurements performed in optimal conditions. The IQC3 is then assayed twice daily and after every new calibration. If results are "out of control", immediate corrective actions are implemented before reports related to the samples analysed in the affected run are issued.
Results
Before the IQC3 introduction, we measured hsTnT on LCS from 26 EQAS exercises, with 11 results (42.3%) not meeting TEa. After the IQC3 introduction, only one out of 21 exercises (4.8%) did not meet TEa (P = 0.009 between the two periods). Results for the failed exercise were 9.1 vs. 7.2 ng/L (TE +26.4%).
Conclusions
Implementing an IQC at hsTn concentrations between LOB and LOD is vital for assuring the suitable accuracy at such low, but clinically relevant concentrations. 
Background-aim
There have been many initiatives to collect and collate benchmarking data on error rates in the Pre and Post-Analytical aspects of Laboratory Medicine. We report here on the findings from the UK where there has been an established pre and post-analytical quality monitoring service (PREPQ) offered by UKNEQAS since 2017, following the Pilot phase from 2014 to 2016. The service is directed by a multi-disciplinary steering group of advisors that includes international experts in the field of pre and post-analytical variables.
Methods
Participating Laboratories submit their error rates for a range of parameters either by Discipline, (e.g. Haematology) or by the whole service (e.g. Blood Sciences). The time periods are Calendar months. To avoid different counting practices Participants may classify their error rates by Request or Specimen.
Participants are regularly offered clinical scenarios presenting pre-or post-analytical errors, which they interpret based on their local practice. An analysis of the responses is shared as a commentary to improve knowledge and drive harmonisation.
Results
The data is normalised into the currency of Sigma Scores, in addition to the raw data, since the size of Laboratories varies by over several orders of magnitude. Trend data is presented in a standard UKNEQAS style familiar to participants. Data has been returned from a maximum of 32 Laboratories for eleven quality indicators. In November 2018, for the key indicators of Sample time/temperature critical failures, the median Sigma Score is 3.85 but the spread is from 2.22 to 4.63. For Patient ID failures the data is a healthier 4.83, with a range of 3.3 to 5.64. Some Laboratories can be at opposite ends of the Sigma Score spectrum for different indicators.
Conclusions
Despite having detailed guidance, there remains confusion as to what data should be collected and how it could be collected in a standardised fashion. The challenge going forward is to review the quality indicators in use against the published literature, to work towards harmonisation of indicators within Europe and to have these built into the specifications for laboratory information management systems. Objective. To assess whether the different method groups for serum alkaline phosphatase (ALP), participating in the SCR 2015 to 2017 programs, perform in a standardized way.
Methods
A set of six control materials, concentrations (56,4 to 278,2 U/L), prepared by Stichting Kwaliteitsbewaking Medische Laboratorium Diagnostiek (SKML, Holland) were distributed in a single shipment to 214 Spanish laboratories who stored it at -20°C until analysis. During 6 consecutive days, a control vial was measured by duplicate in a single analytical run.
Results
3254 results of ALP were grouped according to the combination of measurement procedure-traceability-instrument. Bias of each group mean (percentage deviation to the reference value) was compared with the desirable specification derived from biological variation (6.7%). Intra-laboratory coefficients of variation were calculated and compared with the desirable specification for imprecision derived.
190 out of 214 laboratories used the IFCC recommended method (4-Nitrophenyl phosphate substrate with AMP buffer), traceable to IFCC method; 17 laboratories used same substrate with DEA buffer, 3 laboratories used dry chemistry and 4 did not inform about traceability. From the major group, Beckman AU, Bio-Systems BA and Siemens Dimension/Vista gave standardize results. Abbott Architect and Siemens Advia obtained results slightly below the acceptable limit (deviations of -7.3% and -7.8%, respectively). Roche-Cobas produced the lowest results (-11%). In opposition, 16 laboratories using Siemens Advia with the DEA buffer method, showed highly negative deviant results (-108%).
Conclusions
The 4-Nitrophenyl phosphate substrate with DEA buffer was endorsed to be abandoned.
Further combined work between labs and providers is encouraged, to reduce the discrepancies evidenced in this study for some methods groups. 
Background-aim
When setting analytical performance specifications, models based on the effect on the clinical outcome or on biological variation are preferred. However, for some magnitudes as the ones included in the newborn screening, there is no data available based on these two models. In these cases, quality specifications based on the state-ofthe-art are useful to keep the analytical error under control.
The objective of this work is to obtain quality specifications for the total error (TE) for the magnitudes included in the External Quality Assessment Program (EQA) of newborn screening organized by the Spanish Association of Newborn Screening (AECNE).
Methods
A total of 23,778 results from 19 laboratories were collected from the Spanish EQA in newborn screening during the period between May 2015 and September 2018. Magnitudes included were thyroid-stimulating hormone (TSH), phenylalanine (Phe), tyrosine (Tyr), immunoreactive trypsinogen (IRT), free carnitine (C0), acetylcarnitine (C2), propionylcarnitine (C3), butyrylcarnitine (C4), isovalerylcarnitine (C5), glutarylcarnitine (C5DC), hexanoylcarnitine (C6), octanoylcarnitine (C8), decanoylcarnitine (C10), myristoylcarnitine (C14), palmitoylcarnitine (C16) and stearoylcarnitine (C18).
For each result, TE in percentage was calculated by comparing the value reported by the participant with the target value (robust mean). Quality specifications were calculated as the 90 th percentile, considering only the 75% of each laboratory best results of TE.
Results
The magnitudes that had the best analytical performance were TSH, IRT, C16 and C18, with a TE lower than 20%. For a greater number of magnitudes such as Tyr, C0, C2, C3, C4, C5, C6, C8 and C14, the TE committed were between 20 and 35%. Phe, C5DC and C10 showed the worst analytical performance, with a TE higher than 35%.
Conclusions
TE specifications based on the state-of-the-art for the magnitudes of the Spanish EQA in newborn screening have been established. These data can help laboratories to establish quality specifications for these magnitudes and control their analytical performance. 
Background-aim
Accelerated protocols for acute myocardial infarction (AMI) diagnosis, based on relatively low troponin concentrations and small acute changes of 3-5 ng/L over 1 h in blood, have been validated in several research studies. However, blood samples were typically measured on a single instrument. Therefore, evidence and guidance is required for routine operation and workflow in a centralised laboratory, where serial troponin samples from the same patient might be measured on two different instruments of the same type.
Methods
In this sub-analysis of the multicentre TRAPID-AMI study, we evaluated the performance of the accelerated 0/1-h AMI algorithm when measuring serial troponin samples from the same patient with symptoms suggestive of AMI on two parallel instruments. Patients eligible for inclusion provided informed consent for remeasurements and 707 samples were available. The 0-h and 1-h samples were measured with the Elecsys® Troponin T-high sensitive (cTnT-hs) assay on two different cobas 8000 analysers (Roche Diagnostics). AMI diagnosis was determined by 1-h criteria for rule-out (cTnT-hs b12 ng/L and change b3 ng/L at 1 h) and 0/1-h criteria for rule-in (cTnT-hs N52 ng/L or change N5 ng/L at 1 h); remaining individuals were classified to the observation zone. Outcomes were analysed for different data combinations, e.g. all samples measured, or 0-h and 1-h samples randomly assigned, on the two different instruments.
Results
When running all samples from the same patient on two different instruments of the same type, results were in agreement for 691/707 (97.7%) samples analysed: 354 rule-out, 88 rule-in and 249 observation zone. Results differed (instrument 1/instrument 2) for 16 (2.3%) samples: 1 observation/rule-out; 1 rule-in/observation and 14 rule-out/observation. No reclassifications from rule-in to rule-out were observed and only 1 reclassification from rule-in to observation (0.1%). The potential variation introduced by the parallel instrument setup is thus small compared with variations introduced by an instrument switch when using traditional diagnostic protocols, e.g. a single cutoff.
Conclusions
The 0/1-h algorithm appears to be safe and effective for triaging patients with suspected AMI when measured on two different instruments of the same type. doi:10.1016/j.cca.2019.03.1111
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Accuracy evaluation of five analytical systems for high-and lowdensity lipoprotein cholesterol assays in Korea Medicine, Seoul, South Korea g Korea Centers for Disease Control & Prevention, Chungcheonbuk-do,
South Korea
Background-aim
Accurate and precise measurement of blood cholesterol, including high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C), is essential for generating the correct burden and trends of dyslipidemia. We evaluated the performance of five HDL-C/LDL-C cholesterol assays currently used at clinical laboratory in Korea to assess the traceability of current HDL-C/LDL-C in vitro diagnostic products to commutable frozen serum (CFS) reference materials.
Methods
The HDL-C/LDL-C assays were categorized as five groups according to the combination of instrument and reagent; Toshiba-Kyowa, Hitachi-Sekisui, Siemens ADVIA, Roche Cobas, and Beckman Coulter AU. The 12 levels of CFS pools were prepared according to CLSI 37-A and sent at frozen state. The design based on two days, with one run per day and three replicates per run. Target reference values were measured using reference ultracentrifugation method for HDL-C and ®-quantification for LDL-C at CEQAL. Target performance goal based on the analytical performance criteria for tests used to assess cardiovascular disease risk of the Cholesterol Reference Method Laboratory Network as follows: maximal allowable bias δ ±5% for HDL-C and δ ±4% for LDL-C; maximal allowable imprecision δ 4.0% at ε 42 mg/dL or δ 1.7 at b 42 mg/dL for HDL-C and δ ±4% for LDL-C, In addition we observed total error according to the National Cholesterol Education Program; δ 13% for HDL-C and δ 12% for LDL-C.
Results
The target values of five materials were 37.1 -57.2 mg/dL for HDL-C and 76.9 -130.9 mg/dL for LDL-C. Bias ranged from -0.9% to 6.2% for HDL-C and from −3.3% to 8.5% for LDL-C. Imprecision showed total CVs b 2.2% for HDL-C and b 1.3% for LDL-C. Total error ranged from 3.4% to 6.7% for HDL-C and from 6.2% to 9.2% for LDL-C. Except Toshiba-Kyowa, the other HDL-C assays met target performance goal. Whereas, all five LDL-C assays did not meet target performance goal.
Conclusions
Even routine assays have advanced considerably over recent years, manufacturers' still have to strive for accurate HDL-C/LDL-C measurements for patients with standardization and calibration verification. 
Background-aim
Although the use of EDTA-containing collection tubes is known to stabilize the complement analytes and to make the results more reliable, no external quality assessment (EQA) scheme based on EDTA plasma samples is available to date in France. Consequently, a number of clinical laboratories currently participate to EQA programme on samples whose matrix is different from their routine practice. The aim of this work was to offer a new external quality assessment scheme, as an inter-laboratory exchange (ILE). The different steps of the validation procedure are presented, together with the one-year ILE implementation experience.
Methods
We used the complement Optilite® assays for classical pathway activity, C3c, C4 and C1 inhibitor protein (The Binding Site Group Ltd, Birmingham, UK). Stability studies were performed using the acceptable change limit (ACL), defined as the analytical coefficient of variation (CVa, for each analyte) * 2,77 as the main criteria. The effect of 2 commercial diluents, used to adjust the samples' concentration was studied through the percent of recovery (%R), defined as the proportion of corrected to nondiluted analyte value (acceptable variation: 80-120%).
Results
Validation procedure: (i) whole blood EDTA samples were stable at 4°C up to 72h; (ii) when separated within the 12h of sampling, EDTA plasmas were stable until the 72e hour at 4°C and -20°C but not at room temperature; (iii) no matrix effect was evidenced for the 2 tested commercial diluents; (iv) the diluted samples were stable at -20°C until the 4th week. The ILE program was started on January 2018. A total of 6 sendings of 2 samples was made during the year 2018. From an initial number of 3 participants, we moved to 4 at the 5th sending. Each participating laboratory received a personalized report after each response, together with an annual report of performance. Due to the limited number of participants, both classic and robust z-score were included in the reports. The shipping was systematically controlled using additional samples, and no CV exceeded -10 to +10% when measured back to the laboratory in charge.
Conclusions
The newly implemented ILE will be useful for the accreditation of the complement activity of French laboratories using EDTA plasma samples. 
Background-aim
The presence of Haemoglobin (Haemolysis), Bilirubin (Icterus) and Lipids (Lipaemia) in serum can affect the measurement and reporting of many Clinical Chemistry laboratory test results. Quality Assurance of Serum Indices is not as rigorous as for other Clinical Chemistry assays. Three years ago Birmingham Quality established an EQA scheme for Indices in Serum. This poster explores how the scheme has developed and where we are now.
Methods
The UK NEQAS for Serum Indices (HIL) EQA scheme that not only looks at Haemolysis (H), Icterus (I) and Lipaemia (L) as individual analytes but also looks at the impact these serum indices have on particular specific analytes, which change from month to month, called 'Analyte X'. Three specimens are distributed monthly and laboratories return their H, I, L and 'Analyte X' results, and whether they would report the measured analyte based on the serum indices.
Results
To accommodate the results reported, Birmingham Quality has two data presentationsstandard report format for numerical data, and pie charts for category data. The results returned so far have shown that there are significant differences in practice for the measurement and interpretation of serum indices both within-, and between-manufacturers. For example, an unspiked sample was distributed which had endogenous elevated triglycerides. Beckman Synchron and Beckman AU Olympus identified a significant amount of icterus present, whereas other major methods hadn't. Analytically this is because of secondary interference due to overlapped absorbance not being corrected. Clinically this means that there is the potential that results would not be reported because of an incorrect icterus results being reported on a lipaemic sample, when analytically they may be valid for icterus.
Conclusions
The UK NEQAS for Serum Indices (HIL) has shown that there are significant variations in practice between participants for the use of serum indices which consequently affects patient care both in terms of repeat testing and validity of test results. Unfortunately, EQA alone has not been enough to drive change in laboratory practices as observed by repeat distributions over time showing similar percentages of results that would or would not be reported for Analyte X based on HIL value. 
Background-aim
We sought to define the performance of automated chemistry platforms at two large academic medical centers by calculating and comparing sigma metrics for 28 analytes.
Methods
Performance characteristics of chemistry assays on two Roche Cobas analyzers (University of Florida Health Jacksonville) and four Abbott Architect analyzers (Vanderbilt University Medical Center) were estimated using 12 months of Bio-Rad quality control (QC) data at two concentrations. Method imprecision was calculated as the cumulative QC coefficient of variation (CV) and percent bias was calculated by comparison of analyzer mean to peer group means. Sigma values were calculated for each method as [(TEa -Bias%)/CV%] using allowable total error (TEa) from two sources: the CLIA evaluation limits and desirable biological variation (Ricos C et al.). Average sigma values were generated for each site and graded as optimal N6 sigma; good 5-6 sigma; marginal 3-5 sigma; or poor b3 sigma. Analysis of NIST SRM1950 standards for a subset of analytes allowed an estimation of absolute bias.
Results
Sigma metrics were highly comparable across both study sites. Considering CLIA TEa, just over half (UF 57%; VUMC 54%) of the 28 analytes met the six-sigma standard of performance. Electrolytes (Na, K, Cl, Mg) and metabolites (total bilirubin, BUN, CO2) failed to meet six-sigma. Notably, there were dramatic differences in sigma values calculated using CLIA and Ricos TEa criteria. Almost 40% of the analytes had at least one QC that performed poorly using Ricos. Only 4 of the 28 assays (CK, GGT, Lipase and triglycerides) demonstrated optimal performance at both study sites using Ricos and CLIA criteria. Analysis of NIST SRM1950 at both study sites gave comparable sigmas for all analytes except total bilirubin, cholesterol, Mg and total protein.
Conclusions
Neither Abbott nor Roche analyzers met six-sigma quality standards for all analytes tested. CLIA TEa and RICOS TEa are significantly different, with wider acceptability criteria for CLIA. Variations between individual analyzers and manufacturers and limitations in automation would make tailored QC rules based on sigma metrics difficult to implement in a high-volume laboratory. 
Background-aim
When the Biochemistry department on the Wythenshawe site of Manchester University NHS Foundation Trust first achieved ISO 15189 laboratory accreditation in 2016, this was a big step towards extending the standards to our POCT program. Wythenshawe achieved 22870 accreditation in September 2018, making the department only the second NHS trust to be awarded POCT accreditation in the UK. Based on interest from peer institutions, we propose a roadmap for achieving ISO 22870, using our blood gas testing program as an example.
Methods
Wythenshawe is a 900-bed teaching hospital providing acute care services to adult and paediatric patients. POCT service includes more than 300 devices-29 blood gas analysers, 180 hand-held glucose, ketone, tHb and chemistry devices-equating over 2million individual patient tests each year.
Achieving ISO 22870 involved the efforts of the POCT team, clinical teams, learning and development, the main laboratory and our supplier partners to establish: e-learning, a Quality Management System (QMS), define Key Performance Indicators (KPI), and audit for improvement opportunities.
The blood gas testing service at Wythenshawe includes 29 GEM® Premier™ 5000 with iQM2® (Instrumentation Laboratory) analysers interfaced into GEMweb® Plus which is a key element to the POCT program.
Results
The efforts performed for the blood gas testing can be used as a model for other institutions to achieve ISO 22870:
